CA2601558A1 - Method of treating cancer by administration of 5-substituted nucleosides - Google Patents
Method of treating cancer by administration of 5-substituted nucleosides Download PDFInfo
- Publication number
- CA2601558A1 CA2601558A1 CA002601558A CA2601558A CA2601558A1 CA 2601558 A1 CA2601558 A1 CA 2601558A1 CA 002601558 A CA002601558 A CA 002601558A CA 2601558 A CA2601558 A CA 2601558A CA 2601558 A1 CA2601558 A1 CA 2601558A1
- Authority
- CA
- Canada
- Prior art keywords
- phase
- bvdu
- chemotherapy
- prodrug
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 44
- 201000011510 cancer Diseases 0.000 title claims abstract description 38
- 239000002777 nucleoside Substances 0.000 title claims description 69
- 125000003835 nucleoside group Chemical class 0.000 title description 21
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 claims abstract description 194
- 238000002512 chemotherapy Methods 0.000 claims abstract description 128
- 238000011282 treatment Methods 0.000 claims abstract description 79
- 229940002612 prodrug Drugs 0.000 claims abstract description 76
- 239000000651 prodrug Substances 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 38
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 38
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 24
- 238000011084 recovery Methods 0.000 claims description 99
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 86
- 229960005277 gemcitabine Drugs 0.000 claims description 84
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 35
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 24
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 24
- 239000002254 cytotoxic agent Substances 0.000 claims description 23
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 23
- 201000002528 pancreatic cancer Diseases 0.000 claims description 22
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 21
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 20
- 229960004316 cisplatin Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000003797 telogen phase Effects 0.000 claims description 15
- 230000036765 blood level Effects 0.000 claims description 12
- 230000035572 chemosensitivity Effects 0.000 claims description 11
- 150000003058 platinum compounds Chemical class 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 abstract description 48
- 230000001085 cytostatic effect Effects 0.000 abstract description 39
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 230000002018 overexpression Effects 0.000 abstract description 17
- 230000033616 DNA repair Effects 0.000 abstract description 12
- 108700020796 Oncogene Proteins 0.000 abstract description 10
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 102000043276 Oncogene Human genes 0.000 abstract description 8
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 52
- 230000000694 effects Effects 0.000 description 50
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 230000004083 survival effect Effects 0.000 description 27
- 229960004679 doxorubicin Drugs 0.000 description 26
- 229960004857 mitomycin Drugs 0.000 description 22
- 230000006907 apoptotic process Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 17
- 229930192392 Mitomycin Natural products 0.000 description 16
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 16
- -1 BRCAI/2 Proteins 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 229960000485 methotrexate Drugs 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 11
- 229960001156 mitoxantrone Drugs 0.000 description 11
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 10
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 10
- 108010019092 Uridine phosphorylase Proteins 0.000 description 10
- 102100020892 Uridine phosphorylase 1 Human genes 0.000 description 10
- 238000011278 co-treatment Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000004654 survival pathway Effects 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 7
- 101000644684 Homo sapiens Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 7
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 102100021405 ATP-dependent RNA helicase DDX1 Human genes 0.000 description 5
- 101001041697 Homo sapiens ATP-dependent RNA helicase DDX1 Proteins 0.000 description 5
- 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000439 tumor marker Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 101150022024 MYCN gene Proteins 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 108020001096 dihydrofolate reductase Proteins 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 2
- 102100033501 Interleukin-32 Human genes 0.000 description 2
- 108700012912 MYCN Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102100034961 Poly(rC)-binding protein 2 Human genes 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102100035293 Tropomodulin-2 Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 102100039583 116 kDa U5 small nuclear ribonucleoprotein component Human genes 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101001120734 Ascaris suum Pyruvate dehydrogenase E1 component subunit alpha type I, mitochondrial Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101710109420 DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608799 Homo sapiens 116 kDa U5 small nuclear ribonucleoprotein component Proteins 0.000 description 1
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 1
- 101001056308 Homo sapiens Malate dehydrogenase, cytoplasmic Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000735358 Homo sapiens Poly(rC)-binding protein 2 Proteins 0.000 description 1
- 101001120726 Homo sapiens Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial Proteins 0.000 description 1
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 1
- 101000597772 Homo sapiens Tropomodulin-2 Proteins 0.000 description 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 101150038517 JUN gene Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 102100026475 Malate dehydrogenase, cytoplasmic Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 101710089647 Poly(rC)-binding protein 2 Proteins 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 102100026067 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 101100332446 Rattus norvegicus Ddx39a gene Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 231100000632 Spindle poison Toxicity 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100030306 TBC1 domain family member 9 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108050000004 Tropomodulin-2 Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 108010005279 dichlorophenolindophenol reductase Proteins 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000032147 negative regulation of DNA repair Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to methods of administration of at least one overexpression inhibitor of DNA repair genes and/or oncogenes (e.g., (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), or a prodrug, or salt thereof) to increase the cytotoxic effect of a cytostatic or cytotoxic chemotherapeutic agent during and/or after chemotherapy, e.g., in the treatment of cancer.
Description
METHOD OF TREATING CANCER BY ADMINISTRATION OF
FIELD OF THE INVENTION
[0001] The invention relates to the use of at least one overexpression inhibitor of DNA
repair genes and/or oncogenes for producing a drug to increase the cytotoxic (e.g., apoptotic) effect of cytostatics after chemotherapy.
BACKGROUND
FIELD OF THE INVENTION
[0001] The invention relates to the use of at least one overexpression inhibitor of DNA
repair genes and/or oncogenes for producing a drug to increase the cytotoxic (e.g., apoptotic) effect of cytostatics after chemotherapy.
BACKGROUND
[0002] Cancer diseases in humans are one of the most frequent causes of death and chemotherapy is the most frequent treatment method. The decrease in efficacy of chemotherapy over time is believed to be based on the occurrence of resistance.
[0003] Repeated treatment with cytostatic and/or cytotoxic drugs can lead to induction of chemoresistance and poor prognosis via a number of different mechanisms. Among these, such treatments can lead to overexpression in cancer cells of different survival pathways, of different DNA repair genes, of different oncogenes, and/or of uridine phosphorylase (UPase).
Such treatments can also lead to overexpression of Stat3 and its target VEGF, which can lead to blockade of the initiation of anti-cancer immunity, enhancement of tumor cell proliferation, and/or prevention of apoptosis. Treatment with cytostatic and/or cytotoxic drugs can also lead to downregulation of DT-diaphorase and/or caspases. These factors, singly or in combination, can cause suppression of apoptosis and/or induction of chemoresistance. Suppression of apoptosis, in turn, can lead to genomic instability by recombination and other events and/or amplification of resistance genes like MDR and DHFR.
Such treatments can also lead to overexpression of Stat3 and its target VEGF, which can lead to blockade of the initiation of anti-cancer immunity, enhancement of tumor cell proliferation, and/or prevention of apoptosis. Treatment with cytostatic and/or cytotoxic drugs can also lead to downregulation of DT-diaphorase and/or caspases. These factors, singly or in combination, can cause suppression of apoptosis and/or induction of chemoresistance. Suppression of apoptosis, in turn, can lead to genomic instability by recombination and other events and/or amplification of resistance genes like MDR and DHFR.
[0004] It is believed that these resistances have their root in the fact that cytostatic and/or cytotoxic drugs influence the expression of genes and have a genotoxic effect, i.e., induce mutations, gene amplifications and recombinations and hence destabilize the genome. In this way, chemotherapy induces or selects resistant cancer cells. Often oncogenes, such as e.g.
Ras, Bc12, Bcr-abl, Myc, ErbB2 and others, are affected by such effects induced by cytostatics. Wrongly regulated expression of genes in conjunction with DNA
repair and recombination also contributes to chemoresistance (e.g., p53 gene, BRCAI/2, UBE2N, APEX
and Rad5l). Furthei-more enzymes which metabolize and bioactivate cytostatics (e.g. DHFR, - I -DT-diaphorase (DT-D), or proteins which convey cytostatics (e.g. MDR1), which can lead to chemoresistance.
Ras, Bc12, Bcr-abl, Myc, ErbB2 and others, are affected by such effects induced by cytostatics. Wrongly regulated expression of genes in conjunction with DNA
repair and recombination also contributes to chemoresistance (e.g., p53 gene, BRCAI/2, UBE2N, APEX
and Rad5l). Furthei-more enzymes which metabolize and bioactivate cytostatics (e.g. DHFR, - I -DT-diaphorase (DT-D), or proteins which convey cytostatics (e.g. MDR1), which can lead to chemoresistance.
[0005] Most cytostatics eliminate tumor cells in that they induce apoptosis.
Apoptosis is a form of programmed cell death which was described firstly in Kerr, J. F. et al., Br J Cancer, 26(4) (1972); 239-257 (incorporated by reference herein in its entirety). In contrast to necrosis, apoptosis is a physiological form of cell death. These two forms of cell death can be differentiated by means of differences between necrosis and apoptosis.
Apoptosis has defined morphological and biochemical characteristics which occur successively as events of an ordered cascade. The continuous process can be divided into phases.
Morphological characteristics of apoptosis are core chromatin condensation (karyopyknosis), shrinkage of cytoplasm, formation of apoptotic vesicles and finally apoptotic bodies. Tumor cells can prevent this by overactivation of survival mechanisms. Mechanisms of chemoresistance therefore also comprise anti-apoptotic acting genes, such as e.g. STAT3, the activated "signal transducer and activator of transcription 3" or JUN-D.
Apoptosis is a form of programmed cell death which was described firstly in Kerr, J. F. et al., Br J Cancer, 26(4) (1972); 239-257 (incorporated by reference herein in its entirety). In contrast to necrosis, apoptosis is a physiological form of cell death. These two forms of cell death can be differentiated by means of differences between necrosis and apoptosis.
Apoptosis has defined morphological and biochemical characteristics which occur successively as events of an ordered cascade. The continuous process can be divided into phases.
Morphological characteristics of apoptosis are core chromatin condensation (karyopyknosis), shrinkage of cytoplasm, formation of apoptotic vesicles and finally apoptotic bodies. Tumor cells can prevent this by overactivation of survival mechanisms. Mechanisms of chemoresistance therefore also comprise anti-apoptotic acting genes, such as e.g. STAT3, the activated "signal transducer and activator of transcription 3" or JUN-D.
[0006] In 1995 effects of specific hormones and 5-substituted nucleosides which were hitherto unknown were discovered. These suppress the 2-amino-6-mercaptopurine (AMP)-induced SV40 amplification in cells of the Chinese hamster (Fahrig, R. et al., Mutat Res., 356 (2), 1996, 217-224) (incorporated by reference herein in its entirety) and triethylene melamine-induced recombination in yeasts (Fahrig, R., Mutat. Res., 372 (1), 1996, 133-139) (incorporated by reference herein in its entirety). In EP 0 806 956 B1 and U.S. Patent No.
6,589,941 (incorporated by reference herein in their entireties), the treatment of leukaemia cells of the mouse with 5-substituted nucleosides is described, the doxorubicin (adriamycin)-induced Mdrl gene amplification and chemoresistance having been inhibited.
[00071 In the in vitro tests described above, 5-substituted nucleosides (i.e.
base analogues) had always been applied together with one or more cytostatic or cytotoxic drugs.
[0008] U.S. Patent Publication 2006/0178338 (incorporated by reference herein in its entirety) discloses that 5-substituted nucleosides can increase cytostatic effects of chemotherapy even when administered after a cytotoxic cycle, that is, even when there is no cytotoxic remaining in a patient's system. The document provides in vitro experiments, as well as experiments in rats.
[0009] The prognosis of patients with certain cancers, including, without limitation, advanced pancreatic cancer, is very poor and effective treatments are lacking.
In a pivotal study of gemcitabine (GEM), median survival was still less than 6 months (Glimelius B., et al., "Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer." Ann Oncol 1996; 7[6]:593-600) (incorporated by reference herein in its entirety).
Co-treatment with gemcitabine and erlotinib, the second drug approved for pancreatic cancer, did not show a clinically significant effect. The effect of gemcitabine+erlotinib treatment vs.
gemcitabine+placebo treatment showed increased overall survival (6.37 months vs. 5.9 months, p=0.025), improved one-year survival (24% vs. 17%) and improved time to progression (3.75 months vs. 3.55 months, p=0.003), while skin rash (6% vs.
1%) and diarrhea increased (6% vs. 2%).
[0010] There is a need for drugs and methods to prevent and/or delay the reduction in apoptotic effect caused by resistance formation in cancer treatment, including chemotherapy and/or cytotoxic therapy, and thereby to provide an effective and/or improved treatment method relative to the present state of the art.
[0011] There is a need for drugs and methods including the use of at least one overexpresssion inhibitor of DNA repair genes and/or oncongenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.
[0012] There is a need for drugs and methods to increase and/or improve one-year survival rates among cancer patients and/or to increase patient life span, including, without limitation, patients with pancreatic cancer.
SUMMARY OF THE INVENTION
[0013] The present invention provides a method for treating a cancer treatable with gemcitabine comprising administering to a patient in need thereof a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase and a recovery phase. In a preferred embodiment, the cancer treatable with gemcitabine includes pancreatic cancer.
[0014] The present invention also provides a method for reducing chemoresistance comprising administering to a patient in need thereof a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase.
[0015] The present invention further provides a method for enhancing chemosensitivity comprising administering to a patient in need thereof a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase.
[0016] The present invention further provides a method for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer, comprising administering a therapeutically effective amount of gemcitabine to a cancer patient in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in a recovery phase following the chemotherapy phase.
[0017] In preferred embodiments, methods of the present invention are used to treat patients with pancreatic cancer, and or to treat pancreatic cancer.
[0018] In a preferred embodiment, the BVDU, prodrug or salt thereof comprises the prodrug represented by the formula I:
o NH ~ -O^P_O Br C~\P1 I /
U
NH
CH3, I
or a salt thereof.
[0019] In a preferred embodiment, the invention includes administering the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the chemotherapy phase. In a preferred embodiment, the chemotherapy phase is about 1 to 30 days, preferably about 1 to 5 days.
[0020] In a preferred embodiment, the invention includes administering the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the recovery phase. In a preferred embodiment, the recovery phase is about 1 to 10 days.
[0021] In a preferred embodiment, the method includes a rest phase during which no cytotoxic agent or 5-substituted nucleoside is administered. In a preferred embodiment, the rest phase is about 8 to 60 days.
[0022] In a preferred embodiment, the cytotoxic composition comprises a second cytotoxic agent other than gemcitabine. In a preferred embodiment, the second cytotoxic agent comprises a platinum compound, preferably cisplatin.
[0023] In a preferred embodiment, the 5-substituted nucleoside, prodrug, or salt thereof, or combination of two or more thereof, comprises BVDU, or a prodrug, or salt thereof,.
[0024] In a preferred embodiment, the patient is administered the BVDU, prodrug, or salt thereof during the chemotherapy phase, and attains a BVDU blood level of about 0.02 to 50 g/ml during the chemotherapy phase. Preferably, the patient attains a BVDU AUC
of at least about 0.5 g=hr/ml over a 24-hour period during the chemotherapy phase.
In a preferred embodiment the patient is administered the BVDU, prodrug, or salt thereof during the recovery phase, and attains a BVDU blood level of about 0.02 to 50 g/ml during the recovery phase. Preferably, the patient attains a BVDU AUC of at least about 0.5 g=hr/ml over a 24-hour period during the recovery phase.
[0025] The present invention further provides uses of a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in at least one of a chemotherapy phase and a recovery phase for treating a cancer treatable with gemcitabine in a patient in need thereof. The present invention further provides uses of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase for reducing chemoresistance in a patient in need thereof. The present invention further provides uses of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase for enhancing chemosensitivity in a patient in need thereof. The present invention further provides uses of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in a recovery phase following the chemotherapy phase for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in a cancer patient. The present invention further provides uses of a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in the preparation of a medicament for treating a cancer treatable with gemcitabine in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for treating the cancer in at least one of a chemotherapy phase and a recovery phase. The present invention further provides uses of a therapeutically effective amount of gemcitabine in the preparation of a medicament for reducing chemoresistance in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for reducing chemoresistance in the patient in at least one of the chemotherapy phase or a recovery phase. The present invention further provides uses of a therapeutically effective amount of gemcitabine in the preparation of a medicament for enhancing chemosensitivity in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for enhancing chemosensitivity in the patient in at least one of the chemotherapy phase or a recovery phase. The present invention further provides uses of a therapeutically effective amount of gemcitabine in the preparation of a medicament for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in a cancer patient in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in the preparation of the medicament for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in the cancer patient in a recovery phase following the chemotherapy phase.
[0026] The present invention provides drugs and methods that can increase, e.g., double, survival time. The invention provides drugs and methods for treatment of cancer, preferably pancreatic cancer, including the use of BVDU ((E)-5-(2-bromovinyl)-2'-deoxyuridine) with and/or after GEM, and more preferably in the use of BVDU with and/or after GEM
+
cisplatin (CIS).
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The subject matter according to the invention is explained in more detail with reference to the following figures without limiting the subject matter to the mentioned embodiments.
[0028] Figure 1 shows the effect of a cytostatic alone and in combination with BVDU on the number of AH13r cells.
[0029] Figure 2 shows, in comparison to Figure 1, the results with doxorubicin (DOX), mitoxantrone (MXA) and methotrexate (MTX).
[0030] Figure 3 shows a Western Blot analysis for testing the "survival pathways" with doxorubicin (DOX).
[0031] Figure 4 shows tests with mitomycin (MMC) corresponding to Figure 3.
100321 Figure 5 shows the results of the measurement of DT-diaphorase (DT-D), doxorubicin (DOX) having been used alone or together with BVDU.
[0033] Figure 6 shows tests with methotrexate (MTX) corresponding to Figure 5.
6,589,941 (incorporated by reference herein in their entireties), the treatment of leukaemia cells of the mouse with 5-substituted nucleosides is described, the doxorubicin (adriamycin)-induced Mdrl gene amplification and chemoresistance having been inhibited.
[00071 In the in vitro tests described above, 5-substituted nucleosides (i.e.
base analogues) had always been applied together with one or more cytostatic or cytotoxic drugs.
[0008] U.S. Patent Publication 2006/0178338 (incorporated by reference herein in its entirety) discloses that 5-substituted nucleosides can increase cytostatic effects of chemotherapy even when administered after a cytotoxic cycle, that is, even when there is no cytotoxic remaining in a patient's system. The document provides in vitro experiments, as well as experiments in rats.
[0009] The prognosis of patients with certain cancers, including, without limitation, advanced pancreatic cancer, is very poor and effective treatments are lacking.
In a pivotal study of gemcitabine (GEM), median survival was still less than 6 months (Glimelius B., et al., "Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer." Ann Oncol 1996; 7[6]:593-600) (incorporated by reference herein in its entirety).
Co-treatment with gemcitabine and erlotinib, the second drug approved for pancreatic cancer, did not show a clinically significant effect. The effect of gemcitabine+erlotinib treatment vs.
gemcitabine+placebo treatment showed increased overall survival (6.37 months vs. 5.9 months, p=0.025), improved one-year survival (24% vs. 17%) and improved time to progression (3.75 months vs. 3.55 months, p=0.003), while skin rash (6% vs.
1%) and diarrhea increased (6% vs. 2%).
[0010] There is a need for drugs and methods to prevent and/or delay the reduction in apoptotic effect caused by resistance formation in cancer treatment, including chemotherapy and/or cytotoxic therapy, and thereby to provide an effective and/or improved treatment method relative to the present state of the art.
[0011] There is a need for drugs and methods including the use of at least one overexpresssion inhibitor of DNA repair genes and/or oncongenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.
[0012] There is a need for drugs and methods to increase and/or improve one-year survival rates among cancer patients and/or to increase patient life span, including, without limitation, patients with pancreatic cancer.
SUMMARY OF THE INVENTION
[0013] The present invention provides a method for treating a cancer treatable with gemcitabine comprising administering to a patient in need thereof a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase and a recovery phase. In a preferred embodiment, the cancer treatable with gemcitabine includes pancreatic cancer.
[0014] The present invention also provides a method for reducing chemoresistance comprising administering to a patient in need thereof a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase.
[0015] The present invention further provides a method for enhancing chemosensitivity comprising administering to a patient in need thereof a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase.
[0016] The present invention further provides a method for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer, comprising administering a therapeutically effective amount of gemcitabine to a cancer patient in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in a recovery phase following the chemotherapy phase.
[0017] In preferred embodiments, methods of the present invention are used to treat patients with pancreatic cancer, and or to treat pancreatic cancer.
[0018] In a preferred embodiment, the BVDU, prodrug or salt thereof comprises the prodrug represented by the formula I:
o NH ~ -O^P_O Br C~\P1 I /
U
NH
CH3, I
or a salt thereof.
[0019] In a preferred embodiment, the invention includes administering the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the chemotherapy phase. In a preferred embodiment, the chemotherapy phase is about 1 to 30 days, preferably about 1 to 5 days.
[0020] In a preferred embodiment, the invention includes administering the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the recovery phase. In a preferred embodiment, the recovery phase is about 1 to 10 days.
[0021] In a preferred embodiment, the method includes a rest phase during which no cytotoxic agent or 5-substituted nucleoside is administered. In a preferred embodiment, the rest phase is about 8 to 60 days.
[0022] In a preferred embodiment, the cytotoxic composition comprises a second cytotoxic agent other than gemcitabine. In a preferred embodiment, the second cytotoxic agent comprises a platinum compound, preferably cisplatin.
[0023] In a preferred embodiment, the 5-substituted nucleoside, prodrug, or salt thereof, or combination of two or more thereof, comprises BVDU, or a prodrug, or salt thereof,.
[0024] In a preferred embodiment, the patient is administered the BVDU, prodrug, or salt thereof during the chemotherapy phase, and attains a BVDU blood level of about 0.02 to 50 g/ml during the chemotherapy phase. Preferably, the patient attains a BVDU AUC
of at least about 0.5 g=hr/ml over a 24-hour period during the chemotherapy phase.
In a preferred embodiment the patient is administered the BVDU, prodrug, or salt thereof during the recovery phase, and attains a BVDU blood level of about 0.02 to 50 g/ml during the recovery phase. Preferably, the patient attains a BVDU AUC of at least about 0.5 g=hr/ml over a 24-hour period during the recovery phase.
[0025] The present invention further provides uses of a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in at least one of a chemotherapy phase and a recovery phase for treating a cancer treatable with gemcitabine in a patient in need thereof. The present invention further provides uses of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase for reducing chemoresistance in a patient in need thereof. The present invention further provides uses of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase for enhancing chemosensitivity in a patient in need thereof. The present invention further provides uses of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in a recovery phase following the chemotherapy phase for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in a cancer patient. The present invention further provides uses of a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in the preparation of a medicament for treating a cancer treatable with gemcitabine in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for treating the cancer in at least one of a chemotherapy phase and a recovery phase. The present invention further provides uses of a therapeutically effective amount of gemcitabine in the preparation of a medicament for reducing chemoresistance in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for reducing chemoresistance in the patient in at least one of the chemotherapy phase or a recovery phase. The present invention further provides uses of a therapeutically effective amount of gemcitabine in the preparation of a medicament for enhancing chemosensitivity in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for enhancing chemosensitivity in the patient in at least one of the chemotherapy phase or a recovery phase. The present invention further provides uses of a therapeutically effective amount of gemcitabine in the preparation of a medicament for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in a cancer patient in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in the preparation of the medicament for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in the cancer patient in a recovery phase following the chemotherapy phase.
[0026] The present invention provides drugs and methods that can increase, e.g., double, survival time. The invention provides drugs and methods for treatment of cancer, preferably pancreatic cancer, including the use of BVDU ((E)-5-(2-bromovinyl)-2'-deoxyuridine) with and/or after GEM, and more preferably in the use of BVDU with and/or after GEM
+
cisplatin (CIS).
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The subject matter according to the invention is explained in more detail with reference to the following figures without limiting the subject matter to the mentioned embodiments.
[0028] Figure 1 shows the effect of a cytostatic alone and in combination with BVDU on the number of AH13r cells.
[0029] Figure 2 shows, in comparison to Figure 1, the results with doxorubicin (DOX), mitoxantrone (MXA) and methotrexate (MTX).
[0030] Figure 3 shows a Western Blot analysis for testing the "survival pathways" with doxorubicin (DOX).
[0031] Figure 4 shows tests with mitomycin (MMC) corresponding to Figure 3.
100321 Figure 5 shows the results of the measurement of DT-diaphorase (DT-D), doxorubicin (DOX) having been used alone or together with BVDU.
[0033] Figure 6 shows tests with methotrexate (MTX) corresponding to Figure 5.
-7-[0034] Figure 7 shows the course of disease followed by tumor marker CA19-9.
Solid arrows indicate co-treatment BVDU+GEM+CIS; dashed arrows indicate second line therapy with different cytostatics alone.
[0035] Figure 8 shows additional pilot study results. Median time to progression or median survival according to Box and Whisker and probability of time to progression or of survival according to Kaplan-Meier. Upper line (left graph) and bar "a" (right graph) represent BVDU co-treatment group; lower line (left graph) and bar "b" (right graph) represent chemotherapy alone group; the x's represent one patient without progression and three living patients, respectively.
[0036] Figure 9 shows median survival according to Box and Whisker and probability of time to progression or of survival according to Kaplan-Meier. "X's" represent persons without progression or living patients.
[0037] Figure 10 shows pharmacokinetic results. GEM: The maximum concentrations were measured immediately after completion of the 30 min infusion. BVDU is given half an hour before GEM and the second time 4 hours later. GEM disappeared within this time.
Therefore, an influence on GEM concentration by BVDU could only be exerted by the first intake of tablets. This leads to the result that only two different doses of BVDU (125 and 250 mg) can be compared. BVDU: All measurement is performed within 9 hours.
This means that only the first three intakes of tablets were relevant. In dose groups four and five the intake of tablets was identical.
[0038] Figure 11 illustrates examples of chemotherapy, recovery and treatment phases in pancreas cancer patients.
[0039] Figure 12 shows effect of BVDU alone on tumor size in rats.
[0040] Figure 13 illustrates, without limitation, various treatment schedules.
[0041] Figure 14 illustrates effect of BVDU and cisplatin, with no BVDU in the recovery phase, on tumor size in rats.
Solid arrows indicate co-treatment BVDU+GEM+CIS; dashed arrows indicate second line therapy with different cytostatics alone.
[0035] Figure 8 shows additional pilot study results. Median time to progression or median survival according to Box and Whisker and probability of time to progression or of survival according to Kaplan-Meier. Upper line (left graph) and bar "a" (right graph) represent BVDU co-treatment group; lower line (left graph) and bar "b" (right graph) represent chemotherapy alone group; the x's represent one patient without progression and three living patients, respectively.
[0036] Figure 9 shows median survival according to Box and Whisker and probability of time to progression or of survival according to Kaplan-Meier. "X's" represent persons without progression or living patients.
[0037] Figure 10 shows pharmacokinetic results. GEM: The maximum concentrations were measured immediately after completion of the 30 min infusion. BVDU is given half an hour before GEM and the second time 4 hours later. GEM disappeared within this time.
Therefore, an influence on GEM concentration by BVDU could only be exerted by the first intake of tablets. This leads to the result that only two different doses of BVDU (125 and 250 mg) can be compared. BVDU: All measurement is performed within 9 hours.
This means that only the first three intakes of tablets were relevant. In dose groups four and five the intake of tablets was identical.
[0038] Figure 11 illustrates examples of chemotherapy, recovery and treatment phases in pancreas cancer patients.
[0039] Figure 12 shows effect of BVDU alone on tumor size in rats.
[0040] Figure 13 illustrates, without limitation, various treatment schedules.
[0041] Figure 14 illustrates effect of BVDU and cisplatin, with no BVDU in the recovery phase, on tumor size in rats.
-8-[0042] Figure 15 shows effects of BVDU and doxorubicin on tumor size in rats.
[0043] Figure 16 shows effects of BVDU and cisplatin on tumor size in rats.
[0044] Figure 17 shows effects of BVDU and cyclophosphamide on tumor size in rats.
DETAILED DESCRIPTION OF THE INVENTION
(0045] Unless otherwise stated, a reference to a compound or component includes the compound or component by itself, as well as in combination with other compounds or components, such as mixtures of compounds.
[0046] As used herein, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.
[0047] Except where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not to be considered as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding conventions.
[0048] Additionally, the recitation of numerical ranges within this specification is considered to be a disclosure of all numerical values and ranges within that range. For example, if a range is "from about 1 to 50" (or equivalently, "from about 1 to about 50"), it is deemed to include, for example, 1, 7, 34, 46.1, 23.7, or any other value or range within the range.
[0043] Figure 16 shows effects of BVDU and cisplatin on tumor size in rats.
[0044] Figure 17 shows effects of BVDU and cyclophosphamide on tumor size in rats.
DETAILED DESCRIPTION OF THE INVENTION
(0045] Unless otherwise stated, a reference to a compound or component includes the compound or component by itself, as well as in combination with other compounds or components, such as mixtures of compounds.
[0046] As used herein, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.
[0047] Except where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not to be considered as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding conventions.
[0048] Additionally, the recitation of numerical ranges within this specification is considered to be a disclosure of all numerical values and ranges within that range. For example, if a range is "from about 1 to 50" (or equivalently, "from about 1 to about 50"), it is deemed to include, for example, 1, 7, 34, 46.1, 23.7, or any other value or range within the range.
-9-[0049] Similarly, when a parameter, variable, or other quantity, is described with a set of upper values, and a set of lower values, then this is to be understood as an express disclosure of all ranges formed from each pair of upper and lower values.
[0050] 5-substituted nucleosides useful in the present invention include any 5-subsituted nucleoside that shows an anti-cancer effect when administered with and/or after a cytotoxic treatment cycle. Preferred 5-substituted nucleosides include 5-substituted uridines and derivatives thereof, preferably 5-substituted 2'-deoxyuridines, more preferably BVDU (also known as RP101). Included within this description are protected forms, prodrugs and salts thereof, as well as combinations of one or more thereof. The 5-substituted nucleosides of the present invention are generally referred to as "overexpression inhibitors."
[0051] As the term is used herein, "prodrug" refers to any compound that is metabolized, directly or indirectly, into a 5-substituted nucleoside that shows an anti-cancer effect when administered with and/or after a cytotoxic treatment cycle. Any prodrug can be used within the present invention. An example of a prodrug of BVDU according to the invention is represented in the general formula I:
O
O jH Br cl=~
1] /
CH3, NH
C Allic,`
[0052] As is understood in the art, and as used herein, the terms "protected form" and "prodrug" are interchangeable, the former being predominantly used by chemists, and the latter being predominantly used by pharmacists. Without altering the scope in any regard, the present disclosure will generally employ the term "prodrug" to cover both usages.
[0053] When a salt form is used, any pharmaceutically acceptable salt may be used. Such salts include, but are not limited to acetate, adipate, alginate, arginate, aspartate, benzoate,
[0050] 5-substituted nucleosides useful in the present invention include any 5-subsituted nucleoside that shows an anti-cancer effect when administered with and/or after a cytotoxic treatment cycle. Preferred 5-substituted nucleosides include 5-substituted uridines and derivatives thereof, preferably 5-substituted 2'-deoxyuridines, more preferably BVDU (also known as RP101). Included within this description are protected forms, prodrugs and salts thereof, as well as combinations of one or more thereof. The 5-substituted nucleosides of the present invention are generally referred to as "overexpression inhibitors."
[0051] As the term is used herein, "prodrug" refers to any compound that is metabolized, directly or indirectly, into a 5-substituted nucleoside that shows an anti-cancer effect when administered with and/or after a cytotoxic treatment cycle. Any prodrug can be used within the present invention. An example of a prodrug of BVDU according to the invention is represented in the general formula I:
O
O jH Br cl=~
1] /
CH3, NH
C Allic,`
[0052] As is understood in the art, and as used herein, the terms "protected form" and "prodrug" are interchangeable, the former being predominantly used by chemists, and the latter being predominantly used by pharmacists. Without altering the scope in any regard, the present disclosure will generally employ the term "prodrug" to cover both usages.
[0053] When a salt form is used, any pharmaceutically acceptable salt may be used. Such salts include, but are not limited to acetate, adipate, alginate, arginate, aspartate, benzoate,
-10-benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, citrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecysulfate, ethanesulfonate, fumarate, galacterate, galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate (mesylate), methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, picrate, pivalate, propionate, salicylate, sodium phosphate, stearate, succinate, sulfate, sulfosalicylate, tartrate, thiocyanate, thiomalate, tosylate, and undecanoate, as well as mixtures and combinations of two or more thereof.
[0054] The present invention includes use and/or administration of a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof. It should be understood that when a combination of two or more is used, that it is the combination that is therapeutically effective, and not necessarily the amount of any particular component of the combination. In a combination, particular components may be present in amounts that would be sub-therapeutic if used or administered in isolation.
[0055] It is surprisingly observed that effectiveness of BVDU appears to be independent of the cytostatic drug used or the type of tumor. The present invention can be used with any cancer treatment regime, including radiation therapy and chemotherapy, preferably chemotherapy. As used herein, the terms "cytostatic" and "cytotoxic" will be used interchangeably, and both refer to the active ingredient used in a chemotherapy regime, which active agent may be a single chemical entity, or a combination of two or more entities.
[0056] Cytostatic agents that can be used according to the present invention include agents used for treatment of any type of cancer, including solid and non-solid tumors. These include, without limitation, sarcomas, leukemias, adenocarcinomas, and cancers of the pancreas, lung (including small cell and non-small cell lung cancer), colon, breast, prostate, cervix, liver, brain, bone, ovary, esophagus, stomach and skin. These include agents used against primary tumors, as well as agents used against non-primary cancers, e.g.,
[0054] The present invention includes use and/or administration of a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof. It should be understood that when a combination of two or more is used, that it is the combination that is therapeutically effective, and not necessarily the amount of any particular component of the combination. In a combination, particular components may be present in amounts that would be sub-therapeutic if used or administered in isolation.
[0055] It is surprisingly observed that effectiveness of BVDU appears to be independent of the cytostatic drug used or the type of tumor. The present invention can be used with any cancer treatment regime, including radiation therapy and chemotherapy, preferably chemotherapy. As used herein, the terms "cytostatic" and "cytotoxic" will be used interchangeably, and both refer to the active ingredient used in a chemotherapy regime, which active agent may be a single chemical entity, or a combination of two or more entities.
[0056] Cytostatic agents that can be used according to the present invention include agents used for treatment of any type of cancer, including solid and non-solid tumors. These include, without limitation, sarcomas, leukemias, adenocarcinomas, and cancers of the pancreas, lung (including small cell and non-small cell lung cancer), colon, breast, prostate, cervix, liver, brain, bone, ovary, esophagus, stomach and skin. These include agents used against primary tumors, as well as agents used against non-primary cancers, e.g.,
-11-metastasized tumors, and further include agents characterized as first-line agents, as well as second-line or other agents. The terms, "cytostatic agents", "cytostatics" and "cytotoxic agent" are used interchangeably herein to refer to agents used for treatment of cancer of any type, including solid and non-solid tumors. "Cytostatic agents", "cytostatics"
and "cytotoxic agent" are also referred to herein as "anti-cancer agents".
[0057] As used herein, the term "effective" means that the cytostatic agent in question is effective, in a statistical sense, at treating the type of cancer.
Effectiveness can be assessed by any measure useful for determining effectiveness. Such measures can include, without limitation, half-year or one-year survival rate, median survival, overall survival and/or time to progression (TTP). The term "effective" does not, however, mean that the particular agent was, is, or will be, effective in a particular individual. As used herein, the term "TTP" refers to an interval of time from when a disease is diagnosed (or treated) until the disease worsens, e.g., progresses to the next stage. The term "TTP" can also refer to the length of time a disease spends in a particular stage of progression.
[0058] Cytostatic agents that can be used according to the present invention include agents that work through any mechanism of action. Cytostatic agents used according to the present invention include agents that target cells undergoing DNA synthesis, agents that block progression through the Gl/S-phase boundary, DNA damaging or intercalating agents, spindle poisons and combinations of two or more thereof.
[0059] It is believed that any class of cytostatic agent can be used according to the present invention. Some classes of cytostatic agents that can be used include, without limitation, alkylating agents, anti-metabolites, antibiotics, platinum agents, and combinations of two or more thereof. Some of these include, without limitation, gemcitabine, platinum-based drugs (e.g., cisplatin), etoposide, doxorubicin, vinorelbin, irinotecan, cyclophosphamide, epirubicin, paclitaxel, docetaxel, vincristine, mitoxantrone, mitomycin C, erlotinib, mitoxantrone and methotrexate, and combinations of two or more thereof.
[0060] In a preferred embodiment, the present invention can be used to treat cancers that are treatable with gemcitabine. By this is meant that gemcitabine, alone or in combination with one or more other anti-cancer agents, can be used to treat the cancer.
The term is used in a statistical sense, and does not imply that a given individual will be successfully treated.
and "cytotoxic agent" are also referred to herein as "anti-cancer agents".
[0057] As used herein, the term "effective" means that the cytostatic agent in question is effective, in a statistical sense, at treating the type of cancer.
Effectiveness can be assessed by any measure useful for determining effectiveness. Such measures can include, without limitation, half-year or one-year survival rate, median survival, overall survival and/or time to progression (TTP). The term "effective" does not, however, mean that the particular agent was, is, or will be, effective in a particular individual. As used herein, the term "TTP" refers to an interval of time from when a disease is diagnosed (or treated) until the disease worsens, e.g., progresses to the next stage. The term "TTP" can also refer to the length of time a disease spends in a particular stage of progression.
[0058] Cytostatic agents that can be used according to the present invention include agents that work through any mechanism of action. Cytostatic agents used according to the present invention include agents that target cells undergoing DNA synthesis, agents that block progression through the Gl/S-phase boundary, DNA damaging or intercalating agents, spindle poisons and combinations of two or more thereof.
[0059] It is believed that any class of cytostatic agent can be used according to the present invention. Some classes of cytostatic agents that can be used include, without limitation, alkylating agents, anti-metabolites, antibiotics, platinum agents, and combinations of two or more thereof. Some of these include, without limitation, gemcitabine, platinum-based drugs (e.g., cisplatin), etoposide, doxorubicin, vinorelbin, irinotecan, cyclophosphamide, epirubicin, paclitaxel, docetaxel, vincristine, mitoxantrone, mitomycin C, erlotinib, mitoxantrone and methotrexate, and combinations of two or more thereof.
[0060] In a preferred embodiment, the present invention can be used to treat cancers that are treatable with gemcitabine. By this is meant that gemcitabine, alone or in combination with one or more other anti-cancer agents, can be used to treat the cancer.
The term is used in a statistical sense, and does not imply that a given individual will be successfully treated.
-12-Such cancers include, without limitation, pancreatic cancer, prostate cancer, small cell and non-small cell lung cancer, breast cancer, and ovarian cancer, preferably pancreatic cancer.
[0061] Cytostatics can be used singly or in combination, i.e., a cytostatic composition according to the present invention can include one or more cytostatic agents.
Moreover, a cytostatic composition need not be a single composition, but can include two or more compositions, which can be administered via the same or different route of administration (e.g., IV and/or oral tablet). For example, geincitabine and cisplatin may be administered to a patient via two or more IV containers, and via two or more injection sites. In this example, gemcitabine and cisplatin would be considered, together, to be a cytotoxic composition.
[0062] In general, chemotherapy cycles according to the present invention can be organized in three phases, which will be referred to herein as a chemotherapy phase, a recovery phase, and a rest phase. The only phase in which a cytotoxic agent is administered is the chemotherapy stage, during which a 5-substituted nucleoside may optionally be administered, without limitation, concurrently with, or prior to, administration of the cytotoxic agent. The recovery phase begins after the chemotherapy phase, preferably immediately after. During the recovery phase, no cytotoxic agent is administered, but the recovery phase includes administration of at least one 5-substituted nucleoside, preferably BVDU (or a prodrug, or salt thereof). During the rest phase, no cytotoxic or 5-substituted nucleoside is administered.
While the chemotherapy and recovery phases are described above by administration (or lack of administration) of certain agents, it should be understood that the phases also include periods of time after administration, during which the administered active is still present in therapeutic levels in the patient's system, e.g., in a patient's blood. During the rest phase, typically no cytotoxic or 5-substituted nucleoside is present at therapeutic levels in a patient's system, e.g., in a patient's blood.
[0063] The lengths and patterns of the three phases will depend on a number of factors, such as the cytotoxic agent(s) used, the type and stage of the cancer being treated, and the condition of the patient being treated. The treatment cycles are generally the same in all three clinical study phases, though they may be different. A patient who lives long enough can be treated with several treatment cycles (e.g., 2, 3, 4, 5, 6, 7, 8, or more than 8) of the cytotoxic drugs.
[0061] Cytostatics can be used singly or in combination, i.e., a cytostatic composition according to the present invention can include one or more cytostatic agents.
Moreover, a cytostatic composition need not be a single composition, but can include two or more compositions, which can be administered via the same or different route of administration (e.g., IV and/or oral tablet). For example, geincitabine and cisplatin may be administered to a patient via two or more IV containers, and via two or more injection sites. In this example, gemcitabine and cisplatin would be considered, together, to be a cytotoxic composition.
[0062] In general, chemotherapy cycles according to the present invention can be organized in three phases, which will be referred to herein as a chemotherapy phase, a recovery phase, and a rest phase. The only phase in which a cytotoxic agent is administered is the chemotherapy stage, during which a 5-substituted nucleoside may optionally be administered, without limitation, concurrently with, or prior to, administration of the cytotoxic agent. The recovery phase begins after the chemotherapy phase, preferably immediately after. During the recovery phase, no cytotoxic agent is administered, but the recovery phase includes administration of at least one 5-substituted nucleoside, preferably BVDU (or a prodrug, or salt thereof). During the rest phase, no cytotoxic or 5-substituted nucleoside is administered.
While the chemotherapy and recovery phases are described above by administration (or lack of administration) of certain agents, it should be understood that the phases also include periods of time after administration, during which the administered active is still present in therapeutic levels in the patient's system, e.g., in a patient's blood. During the rest phase, typically no cytotoxic or 5-substituted nucleoside is present at therapeutic levels in a patient's system, e.g., in a patient's blood.
[0063] The lengths and patterns of the three phases will depend on a number of factors, such as the cytotoxic agent(s) used, the type and stage of the cancer being treated, and the condition of the patient being treated. The treatment cycles are generally the same in all three clinical study phases, though they may be different. A patient who lives long enough can be treated with several treatment cycles (e.g., 2, 3, 4, 5, 6, 7, 8, or more than 8) of the cytotoxic drugs.
- 13 -[0064] Any length chemotherapy phase, recovery phase, and/or rest phase may be used in the present invention. A chemotherapy phase, e.g., days in which a chemotherapy agent is administered, will generally be, without limitation, at least about 1, 2, 3, 4, or 5 days long, and generally less than, or about 14, 10, or 7 days long. A recovery phase will generally be, without limitation, at least about 2, 3, 4, 5 or 7 days long, and generally less than about one month (e.g., 30 or 31 days), 4, 3, 2 weeks, 10 or 7 days long. A rest phase will generally be, without limitation, at least about 1 week, 10 days, 2, 3, 4 or 8 weeks long, 1, 2, 3 months long, along with ranges formed from combinations of these times.
[0065] A "treatment phase" can be considered as the combination of chemotherapy phase and recovery phase. In general, without limitation, a treatment phase can be about, or longer than about, 2, 3, or 4-8 treatments within 18, 19 or 30 days. For example, two treatments in 19 days (2 x 1 treatments within 19 days), three treatments in 18 days (3 x 1 treatment within 18 days), 4 to 8 treatments within 30 days, or 1 to 30 treatments within 30 days. The first two of these treatment phases are illustrated in Figure 11. An entire chemotherapy cycle, including all chemotherapy, recovery, and rest phases, will generally be about or less than about 8, 18, 30, 40, 60 or up to 700 days. Without limitation, ranges include, e.g., about 8-700 days.
[0066] In general, a recovery phase can be about, or longer than about two recovery phases of four days each over a 19 day period (2 x 4 days within 19 days) and afterwards a rest phase of at least 10 days before the next cycle starts; three recovery phases of three days each over an 18-day period (3 x 3 days within 18 days) and afterwards a rest phase of at least 10 days before the next cycle starts; 3 to 10 days within 18 days and afterwards a rest phase of up to 60 days before the next cycle starts, or 10 to 60 days recovery phase. A
recovery phase will generally be about or less than 1, 2, 3, 4, 5, 10, 20, 30 or up to 60 days.
Thus, ranges for recovery phases include, e.g., about 5-20 days, or 1-60 days.
[0067] The 5-substituted nucleoside may be present at or above any amount in the blood that is effective. Amounts should not be so high as to induce unacceptable side effects, although drugs might be used to ameliorate side effects. Levels of 5-substituted nucleoside need not be the same in the recovery phase as in the chemotherapy phase.
Indeed, because of the absence of chemotherapy agents (which can induce strong side effects) in the recovery phase, it might be possible to employ higher levels of 5-substituted nucleosides during the
[0065] A "treatment phase" can be considered as the combination of chemotherapy phase and recovery phase. In general, without limitation, a treatment phase can be about, or longer than about, 2, 3, or 4-8 treatments within 18, 19 or 30 days. For example, two treatments in 19 days (2 x 1 treatments within 19 days), three treatments in 18 days (3 x 1 treatment within 18 days), 4 to 8 treatments within 30 days, or 1 to 30 treatments within 30 days. The first two of these treatment phases are illustrated in Figure 11. An entire chemotherapy cycle, including all chemotherapy, recovery, and rest phases, will generally be about or less than about 8, 18, 30, 40, 60 or up to 700 days. Without limitation, ranges include, e.g., about 8-700 days.
[0066] In general, a recovery phase can be about, or longer than about two recovery phases of four days each over a 19 day period (2 x 4 days within 19 days) and afterwards a rest phase of at least 10 days before the next cycle starts; three recovery phases of three days each over an 18-day period (3 x 3 days within 18 days) and afterwards a rest phase of at least 10 days before the next cycle starts; 3 to 10 days within 18 days and afterwards a rest phase of up to 60 days before the next cycle starts, or 10 to 60 days recovery phase. A
recovery phase will generally be about or less than 1, 2, 3, 4, 5, 10, 20, 30 or up to 60 days.
Thus, ranges for recovery phases include, e.g., about 5-20 days, or 1-60 days.
[0067] The 5-substituted nucleoside may be present at or above any amount in the blood that is effective. Amounts should not be so high as to induce unacceptable side effects, although drugs might be used to ameliorate side effects. Levels of 5-substituted nucleoside need not be the same in the recovery phase as in the chemotherapy phase.
Indeed, because of the absence of chemotherapy agents (which can induce strong side effects) in the recovery phase, it might be possible to employ higher levels of 5-substituted nucleosides during the
-14-recovery phase than in the chemotherapy phase. Higher levels of 5-substituted nucleosides during the chemotherapy phase than in the recovery phase are also contemplated in this invention.
[0068] When BVDU is used (or a prodrug, or salt thereof), BVDU may be present in at least a therapeutically-effective amount, preferably a blood concentration of BVDU of at least about 0.02 ICg/ml, more preferably at least about 0.05 g/ml, more preferably at least about 0.5 pg/ml. It is expected that blood levels may be kept below about 50 g/ml, or below about 20, or about 10, or about 5 g/ml. Ranges may be defined (here and throughout this document) by any combination of upper and lower bounds, e.g., about 0.05 to 20 g/ml.
Figure 12 illustrates some BVDU blood levels obtained from patients in clinical trials. The data on which Figure 12 is based are presented in Tables 1 and 2, below. Table I shows day-1 blood sampling and dosing schedules for BVDU and gemcitabine. Table 2 shows plasma concentrations of BVDU (ng/mL) obtained after oral administration of BVDU (day-1 values).
Table 1 Time Drug Gemcitabine BVDU
(hr) Administered Sample Sample Pre-dose - X X
0.5 - - X
1.0 Start of Gemzar X X
infusion 1.5 End of Gemzar X
infusion 2.0 - X X
3.0 - X X
4.0 BVDU - X
5.0 - x x 8.0 BVDU - -9.0 - X X
12.0 BVDU - -
[0068] When BVDU is used (or a prodrug, or salt thereof), BVDU may be present in at least a therapeutically-effective amount, preferably a blood concentration of BVDU of at least about 0.02 ICg/ml, more preferably at least about 0.05 g/ml, more preferably at least about 0.5 pg/ml. It is expected that blood levels may be kept below about 50 g/ml, or below about 20, or about 10, or about 5 g/ml. Ranges may be defined (here and throughout this document) by any combination of upper and lower bounds, e.g., about 0.05 to 20 g/ml.
Figure 12 illustrates some BVDU blood levels obtained from patients in clinical trials. The data on which Figure 12 is based are presented in Tables 1 and 2, below. Table I shows day-1 blood sampling and dosing schedules for BVDU and gemcitabine. Table 2 shows plasma concentrations of BVDU (ng/mL) obtained after oral administration of BVDU (day-1 values).
Table 1 Time Drug Gemcitabine BVDU
(hr) Administered Sample Sample Pre-dose - X X
0.5 - - X
1.0 Start of Gemzar X X
infusion 1.5 End of Gemzar X
infusion 2.0 - X X
3.0 - X X
4.0 BVDU - X
5.0 - x x 8.0 BVDU - -9.0 - X X
12.0 BVDU - -
-15-Table 2 BVDU Time (hr) Dose patient Level 0.0 0.5 1.0 1.5 2.0 3.0 4.0 5.0 9.0 (m 6000 Mean 0 213 177 250 231 175 113 300 391 Min 0 106 82 114 120 116 90 73 138 Median 0 213 109 226 207 133 122 334 403 Max 0 320 339 411 366 277 126 458 620 CV% . 71.0 79.9 59.9 54.0 50.4 17.5 56.0 55.0 Mean 0 1604 872 555 454 302 243 641 952 Min 0 132 224 196 227 198 112 188 360 Median 0 1126 484 644 403 304 242 776 898 Max 0 4574 2008 848 792 444 418 1146 1986 CV% . 111.4 83.5 48.6 52.0 34.3 47.2 62.4 68.8
-16-Table 2 (cont'd) BVDU Time (hr) Dose Patient Level 0.0 0.5 1.0 1.5 2.0 3.0 4.0 5.0 9.0 (mg) 9000 Mean 0 942 784 697 701 464 420 1304 1509 Min 0 234 93 62 366 282 198 484 348 Median 0 979 781 530 705 441 378 1020 1633 Max 0 1574 1480 1666 1029 693 726 2690 2420 CV% . 74.7 91.1 107.1 40.2 43.8 54.8 74.9 56.9 112 . 188 420 506 1136 308 130 410 1150 204 0 290 1012 138 122 . . 240 1386 Mean 0 1111 1011 636 697 453 206 400 2068 Min 0 188 420 138 122 228 88 202 1084 Median 0 1154 1012 566 669 279 212 410 1386 Max 0 2202 1648 1100 1136 1026 310 702 4788 CV% . 79.1 43.3 57.7 60.2 84.7 55.0 49.7 75.3
-17-Table 2 (cont'd) BVDU Time (hr) Dose Patient Level 0.0 0.5 1.0 1.5 2.0 3.0 4.0 5.0 9.0 (mg) Mean 0 1486 1164 1053 904 738 543 2077 2345 Min 0 452 647 792 362 268 392 200 1220 Median 0 672 1018 844 561 407 440 1074 1778 Max 0 3334 1826 1524 1788 1540 796 4958 4038 CV% . 108.0 51.8 38.8 85.5 94.5 40.7 121.9 63.6 [0069] When a combination of two or more 5-substituted nucleosides, or prodrugs or salts thereof, is used or administered, the combination may be administered in any way, including, without limitation, orally (including, without limitation, via tablet, capsule, or orally disintegrating form), parenterally (including, without limitation, intravenously, via bolus injection or slow infusion), or by other means (including, without limitation, transdermally).
The components of a combination may be administered in the same dosage fonn (e.g., all components present in a single tablet), in different dosage forms (e.g., different components among two or more tablets), or by different route of administration (e.g., different components administered parenterally and orally), and they may be administered simultaneously, or sequentially. Administration is preferably oral. Dosage forms are preferably oral dosage forms, more preferably tablets. Dosage forms for combinations preferably include all 5-substituted nucleosides, prodrugs and/or salts thereof, in a single dosage form, preferably an oral dosage form, preferably a capsule or tablet.
[0070] BVDU, or prodrug or salt thereof, may be administered in any way, and by any route of administration, via any dosage form, that results in obtaining a therapeutically effective amount of BVDU in a patient. BVDU, or prodrug or salt thereof, may be administered orally (including, without limitation, via tablet, capsule, or orally disintegrating form), parenterally (including, without limitation, intravenously, via bolus injection or slow infusion), or by other means (including, without limitation, transdermally).
Combinations of two or more dosage forms and/or routes of administration are also included in the present
The components of a combination may be administered in the same dosage fonn (e.g., all components present in a single tablet), in different dosage forms (e.g., different components among two or more tablets), or by different route of administration (e.g., different components administered parenterally and orally), and they may be administered simultaneously, or sequentially. Administration is preferably oral. Dosage forms are preferably oral dosage forms, more preferably tablets. Dosage forms for combinations preferably include all 5-substituted nucleosides, prodrugs and/or salts thereof, in a single dosage form, preferably an oral dosage form, preferably a capsule or tablet.
[0070] BVDU, or prodrug or salt thereof, may be administered in any way, and by any route of administration, via any dosage form, that results in obtaining a therapeutically effective amount of BVDU in a patient. BVDU, or prodrug or salt thereof, may be administered orally (including, without limitation, via tablet, capsule, or orally disintegrating form), parenterally (including, without limitation, intravenously, via bolus injection or slow infusion), or by other means (including, without limitation, transdermally).
Combinations of two or more dosage forms and/or routes of administration are also included in the present
-18-invention. Administration is preferably oral. Dosage forms are preferably oral dosage forms, more preferably tablets.
[0071] Any amount of BVDU that results in effective blood levels can be used in accordance with this invention, and may depend on the size and condition of the patient.
BVDU is preferably administered in amounts greater than, or about, 100, 250 or 500 mg daily. BVDU is preferably administered in amounts less than, or about 3000, 2000, or 1500 mg daily. Some representative non-limiting levels of BVDU administered per day include amounts of, or about, e.g., 500, 625, 750, 875, 1000 or 1500 mg daily.
[0072] In order to maintain effective blood levels, the 5-substituted nucleoside, e.g., BVDU, is preferably administered over 3, 4 or 5, preferably 4, divided doses daily.
Representative doses of BVDU include 500 mg daily, which can be administered as, e.g., 4 divided doses of 125 mg each (4x125 mg); 625 mg, which can be administered as, e.g., 1x250 mg + 3x125 mg daily; 750 mg, which can be administered as, e.g., 2x250 mg + 2x125 mg daily; 875 mg, which can be administered as, e.g., 3x250 mg + 1x125 mg daily; or 1000 mg, which can be administered as, e.g., 4x250 mg daily. The dosage can also be increased over a chemotherapy and/or recovery phase, or can be increased from one recovery phase to another. Thus, for example, 500 mg can be administered daily over one chemotherapy and/or recovery phase, which can be increased to, e.g., 625 mg daily in a following chemotherapy and/or recovery phase. Reductions in dosage of 5-substituted nucleoside, e.g., BVDU, are also within the scope of the present invention.
[0073] The number of doses administered on a daily basis can be reduced by administration of modified release dosage forms. Such forms include without limitation, oral forms (e.g., controlled, extended and/or sustained release dosage forms), and transdermal forms (e.g., extended release patches). Such dosage forms may result in improved patient acceptance and/or compliance. Such dosage forms may permit attaining similar or superior pharmacokinetic parameters (e.g., Tmax, Cmax and/or AUC) compared to instant release dosage forms. Without limitation, modified release dosage forms can be administered, e.g., 1, 2, 3 or 4 times per day.
[0074] Any effective pharmacokinetic parameters may be employed with the present invention. Preferred pharmacokinetic parameters provide for pharmaceutically effective
[0071] Any amount of BVDU that results in effective blood levels can be used in accordance with this invention, and may depend on the size and condition of the patient.
BVDU is preferably administered in amounts greater than, or about, 100, 250 or 500 mg daily. BVDU is preferably administered in amounts less than, or about 3000, 2000, or 1500 mg daily. Some representative non-limiting levels of BVDU administered per day include amounts of, or about, e.g., 500, 625, 750, 875, 1000 or 1500 mg daily.
[0072] In order to maintain effective blood levels, the 5-substituted nucleoside, e.g., BVDU, is preferably administered over 3, 4 or 5, preferably 4, divided doses daily.
Representative doses of BVDU include 500 mg daily, which can be administered as, e.g., 4 divided doses of 125 mg each (4x125 mg); 625 mg, which can be administered as, e.g., 1x250 mg + 3x125 mg daily; 750 mg, which can be administered as, e.g., 2x250 mg + 2x125 mg daily; 875 mg, which can be administered as, e.g., 3x250 mg + 1x125 mg daily; or 1000 mg, which can be administered as, e.g., 4x250 mg daily. The dosage can also be increased over a chemotherapy and/or recovery phase, or can be increased from one recovery phase to another. Thus, for example, 500 mg can be administered daily over one chemotherapy and/or recovery phase, which can be increased to, e.g., 625 mg daily in a following chemotherapy and/or recovery phase. Reductions in dosage of 5-substituted nucleoside, e.g., BVDU, are also within the scope of the present invention.
[0073] The number of doses administered on a daily basis can be reduced by administration of modified release dosage forms. Such forms include without limitation, oral forms (e.g., controlled, extended and/or sustained release dosage forms), and transdermal forms (e.g., extended release patches). Such dosage forms may result in improved patient acceptance and/or compliance. Such dosage forms may permit attaining similar or superior pharmacokinetic parameters (e.g., Tmax, Cmax and/or AUC) compared to instant release dosage forms. Without limitation, modified release dosage forms can be administered, e.g., 1, 2, 3 or 4 times per day.
[0074] Any effective pharmacokinetic parameters may be employed with the present invention. Preferred pharmacokinetic parameters provide for pharmaceutically effective
-19-levels of cytotoxic agents and of 5-substituted nucleoside. Generally, preferred lower levels of Cmax and AUC are determinable from lowest levels that are pharmaceutically effective.
Generally, preferred upper levels of Cmax and AUC are determined by the desire to avoid side-effects, and/or avoid drug wastage. Any Cmax for 5-substituted nucleoside that is pharmaceutically effective is within the scope of the present invention.
Without limiting the present invention, preferred Cmax levels for 5-substituted nucleosides are at least about 0.1, 0.5, or I g/ml of blood, and are preferably less than or about 8, 3, or 41tg/ml. Preferred AUC levels for 5-substituted nucleosides over a 24-hour period are preferably at least about 0.5, 1, or 2 hr= g/m1, and preferably less than or about 10, 6, or 5 hr= g/ml.
[0075] The cytotoxic agent(s) may remain constant over one or more chemotherapy phases (e.g., may remain the same compounds and/or dosage levels). It is also within the scope of the present invention to vary the compounds and/or dosage levels of cytotoxic agent(s). Such varying may be within a chemotherapy phase or cycle, from one chemotherapy phase or cycle to another, or both. In a preferred embodiment, the dosage of cytotoxic increases within a chemotherapy phase or cycle. When the dosage of cytotoxic agent(s) increases, the dosage of 5-substituted nucleoside, e.g., BVDU, may remain constant or may increase or decrease, and preferably will remain constant.
[0076] Without being limited by theory, it is believed that in cultured human pancreatic tumor cells, BVDU inhibits gene products involved in DNA repair such as APEX1, which was also a main effect observed in other tumor cell lines. Treatment with GEM
or other cytostatic drugs leads to apurinic sites, which triggers DNA repair, including the induction of APEX1 to restore DNA replication and genetic integrity. Thus, inhibition of DNA repair genes like APEX1 during anticancer treatment increases chemosensitivity, because it was shown that silencing of APEX1 expression by RNA interference enhanced DNA
nicking and nearly doubled specific cell lysis.
[0077] BVDU downregulates uridine phosphorylase (UPase) expression in BxPC-3 and AsPC-1 human pancreas carcinoma cell lines. It is demonstrated that UPase is highly expressed in a panel of pancreas cancer cell lines and that UPase can potentially be useful in tumor targeting and as a tumor marker. In squamous cell carcinoma, high staining of UPase in primary tumors was frequently associated with the presence of lymph node metastases and
Generally, preferred upper levels of Cmax and AUC are determined by the desire to avoid side-effects, and/or avoid drug wastage. Any Cmax for 5-substituted nucleoside that is pharmaceutically effective is within the scope of the present invention.
Without limiting the present invention, preferred Cmax levels for 5-substituted nucleosides are at least about 0.1, 0.5, or I g/ml of blood, and are preferably less than or about 8, 3, or 41tg/ml. Preferred AUC levels for 5-substituted nucleosides over a 24-hour period are preferably at least about 0.5, 1, or 2 hr= g/m1, and preferably less than or about 10, 6, or 5 hr= g/ml.
[0075] The cytotoxic agent(s) may remain constant over one or more chemotherapy phases (e.g., may remain the same compounds and/or dosage levels). It is also within the scope of the present invention to vary the compounds and/or dosage levels of cytotoxic agent(s). Such varying may be within a chemotherapy phase or cycle, from one chemotherapy phase or cycle to another, or both. In a preferred embodiment, the dosage of cytotoxic increases within a chemotherapy phase or cycle. When the dosage of cytotoxic agent(s) increases, the dosage of 5-substituted nucleoside, e.g., BVDU, may remain constant or may increase or decrease, and preferably will remain constant.
[0076] Without being limited by theory, it is believed that in cultured human pancreatic tumor cells, BVDU inhibits gene products involved in DNA repair such as APEX1, which was also a main effect observed in other tumor cell lines. Treatment with GEM
or other cytostatic drugs leads to apurinic sites, which triggers DNA repair, including the induction of APEX1 to restore DNA replication and genetic integrity. Thus, inhibition of DNA repair genes like APEX1 during anticancer treatment increases chemosensitivity, because it was shown that silencing of APEX1 expression by RNA interference enhanced DNA
nicking and nearly doubled specific cell lysis.
[0077] BVDU downregulates uridine phosphorylase (UPase) expression in BxPC-3 and AsPC-1 human pancreas carcinoma cell lines. It is demonstrated that UPase is highly expressed in a panel of pancreas cancer cell lines and that UPase can potentially be useful in tumor targeting and as a tumor marker. In squamous cell carcinoma, high staining of UPase in primary tumors was frequently associated with the presence of lymph node metastases and
-20-lower overall survival. Breast carcinoma patients with high UPase levels had a worse prognosis than those with low levels.
[0078] Because of the multiplicity of mechanisms of action it is difficult to understand which mechanism or mechanisms are responsible for the therapeutic effect of the BVDU
combination chemotherapy. The numerous immunomodulatory and chemosensitizing properties of BVDU are probably working in concert to optimize chemotherapy and to inhibit chemoresistance.
[0079] Without being bound by theory, it is believed that 5-substituted nucleosides can prevent, reduce, or delay induction of chemoresistance and/or poor prognosis, and can do so when administered during and/or after administration of cytotoxics; when cytotoxics are or are not in a patient's system. It is believed that there are several different mechanism by which 5-substituted nucleosides, preferably BVDU (or a prodrug or salt thereof) can accomplish this. It is possible that BVDU (or a prodrug or salt thereof) may act to inhibit overexpression of different survival pathways; of DNA repair genes such as, without limitation, UBE2N and/or APEX1; of oncogenes such as, without limitation, STAT3, DDX1, and/or JUN-D; and/or of uridine phosphorylase (UPase). It is also possible that BVDU (or a prodrug or salt thereof) inhibits overexpression of STAT3 and its target VEGF, potentially leading to activation of anti-tumor immunity by overexpression of lymphotoxins a and 0, natural killer cell transcript 4 (NK4), tumor necrosis factor LIGHT/TNFSF-14, ICAM-1;
inhibition of tumor proliferation, and/or maintenance of apoptosis. It is also possible that BVDU upregulates DT-diaphorase and/or caspase 3. Without being bound by theory, it is believed that these factors, singly or in combination, can lead to induction of apoptosis and maintenance of chemosensitivity. Maintenance of apoptosis, in turn, can lead to suppression of induces recombination and/or suppression of amplification resistance genes such as, without limitation, MDR and DHFR.
[0080] Of concern here are above all the DNA repair genes and/or oncogenes whose expression and/or overexpression can be regulated with a 5-substituted nucleoside. The DNA
repair genes and/or oncogenes include, but are not limited to, UBE2N, APEX, DDX1, STAT3, VEGF and/or JUN-D.
[0078] Because of the multiplicity of mechanisms of action it is difficult to understand which mechanism or mechanisms are responsible for the therapeutic effect of the BVDU
combination chemotherapy. The numerous immunomodulatory and chemosensitizing properties of BVDU are probably working in concert to optimize chemotherapy and to inhibit chemoresistance.
[0079] Without being bound by theory, it is believed that 5-substituted nucleosides can prevent, reduce, or delay induction of chemoresistance and/or poor prognosis, and can do so when administered during and/or after administration of cytotoxics; when cytotoxics are or are not in a patient's system. It is believed that there are several different mechanism by which 5-substituted nucleosides, preferably BVDU (or a prodrug or salt thereof) can accomplish this. It is possible that BVDU (or a prodrug or salt thereof) may act to inhibit overexpression of different survival pathways; of DNA repair genes such as, without limitation, UBE2N and/or APEX1; of oncogenes such as, without limitation, STAT3, DDX1, and/or JUN-D; and/or of uridine phosphorylase (UPase). It is also possible that BVDU (or a prodrug or salt thereof) inhibits overexpression of STAT3 and its target VEGF, potentially leading to activation of anti-tumor immunity by overexpression of lymphotoxins a and 0, natural killer cell transcript 4 (NK4), tumor necrosis factor LIGHT/TNFSF-14, ICAM-1;
inhibition of tumor proliferation, and/or maintenance of apoptosis. It is also possible that BVDU upregulates DT-diaphorase and/or caspase 3. Without being bound by theory, it is believed that these factors, singly or in combination, can lead to induction of apoptosis and maintenance of chemosensitivity. Maintenance of apoptosis, in turn, can lead to suppression of induces recombination and/or suppression of amplification resistance genes such as, without limitation, MDR and DHFR.
[0080] Of concern here are above all the DNA repair genes and/or oncogenes whose expression and/or overexpression can be regulated with a 5-substituted nucleoside. The DNA
repair genes and/or oncogenes include, but are not limited to, UBE2N, APEX, DDX1, STAT3, VEGF and/or JUN-D.
-21-[0081] Preferably, a 5-substituted nucleoside, prodrug, or salt thereof, is used as overexpression inhibitor.
[0082] Preferably, at least one cytostatic in conjunction with at least one overexpression inhibitor of DNA repair gene and/or oncogene or a drug containing the overexpression inhibitor was already used during chemotherapy.
[0083] Surprisingly it was able to be shown that, after completion of chemotherapy, if the cells grow further solely with 5-substituted nucleosides (base analogues), the growth thereof is inhibited even more than if the chemotherapy had been continued with cytostatics.
Completely unexpectedly, the effect of the 5-substituted nucleosides (base analogues) increases, instead of decreasing, after completion of the chemotherapy phase (treatment).
[0084] This effect was established by means of a screening system according to the invention. This screening method is based on the treatment of tumor cells during a chemotherapy cycle over a period of preferably eight to thirty days with increasing doses of a cytostatic and a constant dose of the overexpression inhibitor. After this combination treatment, the cytostatic is discontinued and the treatment is continued solely with the overexpression inhibitor. This recovery phase (also called recovery phase) lasts preferably between 3 and 10 days. Chemotherapy cycles of this type can be implemented successively up to 6 times.
[0085] These unexpected results suggest a constellation of treatment forms which would have been surprising for the person skilled in the art:
- 5-substituted nucleosides, given alone (i.e., not with or after a cytostatic), show no effect.
- 5-substituted nucleosides, given together with a cytostatic, show an effect.
- 5-substituted nucleosides, given alone, after they had been given in advance together with a cytostatic (recovery phase), show an increased effect.
[0086] Without being bound by theory, it is believed that the observed effect, i.e. the inhibition of chemoresistance and increase in chemosensitivity, can be described as a toxic maintenance of cytostatics-induced apoptosis by influencing the gene expression of specific genes. It is believed that this takes place by:
[0082] Preferably, at least one cytostatic in conjunction with at least one overexpression inhibitor of DNA repair gene and/or oncogene or a drug containing the overexpression inhibitor was already used during chemotherapy.
[0083] Surprisingly it was able to be shown that, after completion of chemotherapy, if the cells grow further solely with 5-substituted nucleosides (base analogues), the growth thereof is inhibited even more than if the chemotherapy had been continued with cytostatics.
Completely unexpectedly, the effect of the 5-substituted nucleosides (base analogues) increases, instead of decreasing, after completion of the chemotherapy phase (treatment).
[0084] This effect was established by means of a screening system according to the invention. This screening method is based on the treatment of tumor cells during a chemotherapy cycle over a period of preferably eight to thirty days with increasing doses of a cytostatic and a constant dose of the overexpression inhibitor. After this combination treatment, the cytostatic is discontinued and the treatment is continued solely with the overexpression inhibitor. This recovery phase (also called recovery phase) lasts preferably between 3 and 10 days. Chemotherapy cycles of this type can be implemented successively up to 6 times.
[0085] These unexpected results suggest a constellation of treatment forms which would have been surprising for the person skilled in the art:
- 5-substituted nucleosides, given alone (i.e., not with or after a cytostatic), show no effect.
- 5-substituted nucleosides, given together with a cytostatic, show an effect.
- 5-substituted nucleosides, given alone, after they had been given in advance together with a cytostatic (recovery phase), show an increased effect.
[0086] Without being bound by theory, it is believed that the observed effect, i.e. the inhibition of chemoresistance and increase in chemosensitivity, can be described as a toxic maintenance of cytostatics-induced apoptosis by influencing the gene expression of specific genes. It is believed that this takes place by:
-22-1) Blockade of "survival pathways" in the recovery phase.
2) Blockade of DNA repair of associated enzymes.
3) Induction of DT-diaphorase activity.
4) Reduced expression of ATP-generated enzymes in the recovery phase.
[0087] With respect to 1), base analogues such as BVDU block "survival pathways"
principally in the recovery phase of the co-treatment after discontinuing the cytostatics and consequently enforce the course of apoptosis.
[0088] By means of HOPI double coloration of AH13r tumor cells of the rat, it was able to be detected that cytostatics such as doxorubicin (DOX), mitoxantrone (MXA) or mitomycin C (MMC) initiate apoptosis. Co-treatment with the base analogue (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) promotes apoptosis by blockade of anti-apoptotic "survival pathways" which include STAT3 and JUN-D.
[0089] This effect occurs firstly in the recovery phase of the cells, as can be seen in Example 2.
[0090] Constitutively activated STAT3 has an oncogenic effect and contributes to the development of different human cancer diseases. This occurs by inhibition of apoptosis. In this way, STAT3 facilitates the survival of tumor cells and makes cells resistant to chemotherapy. Correspondingly, the inhibition of "STAT3 signaling" induces apoptosis and increases the sensitivity to cytostatics.
[0091] JUN-D, a member of the JUN gene family, is an essential component of the "activating protein-1" (AP-1) transcription factor complex with omnipresent expressivity.
JUN-D(-'-) primary fibroblasts show premature ageing and increased apoptosis after UV
radiation or TNFa treatment. This result leads to the supposition that JUN-D
activates the "NFkappaB survival pathway". Furthermore, p202, which is regulated directly by JUN-D, makes fibroblasts able to resist apoptosis.
2) Blockade of DNA repair of associated enzymes.
3) Induction of DT-diaphorase activity.
4) Reduced expression of ATP-generated enzymes in the recovery phase.
[0087] With respect to 1), base analogues such as BVDU block "survival pathways"
principally in the recovery phase of the co-treatment after discontinuing the cytostatics and consequently enforce the course of apoptosis.
[0088] By means of HOPI double coloration of AH13r tumor cells of the rat, it was able to be detected that cytostatics such as doxorubicin (DOX), mitoxantrone (MXA) or mitomycin C (MMC) initiate apoptosis. Co-treatment with the base analogue (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) promotes apoptosis by blockade of anti-apoptotic "survival pathways" which include STAT3 and JUN-D.
[0089] This effect occurs firstly in the recovery phase of the cells, as can be seen in Example 2.
[0090] Constitutively activated STAT3 has an oncogenic effect and contributes to the development of different human cancer diseases. This occurs by inhibition of apoptosis. In this way, STAT3 facilitates the survival of tumor cells and makes cells resistant to chemotherapy. Correspondingly, the inhibition of "STAT3 signaling" induces apoptosis and increases the sensitivity to cytostatics.
[0091] JUN-D, a member of the JUN gene family, is an essential component of the "activating protein-1" (AP-1) transcription factor complex with omnipresent expressivity.
JUN-D(-'-) primary fibroblasts show premature ageing and increased apoptosis after UV
radiation or TNFa treatment. This result leads to the supposition that JUN-D
activates the "NFkappaB survival pathway". Furthermore, p202, which is regulated directly by JUN-D, makes fibroblasts able to resist apoptosis.
-23-[0092] Co-treatment by BVDU reduced the expression of both JUN-D isoforms by approximately one quarter. In contrast, STAT3 was regulated in the recovery phase by approximately two thirds (Example 2).
[0093] The effect in the recovery phase after co-treatment with mytomycin C is particularly impressive. Here, the base analogue reduces the overexpression of the oncogene JUN-D to the control level (Example 2).
[00941 With respect to 2), base analogues such as BVDU block DDXl. DDX1 is co-amplified with MYCN and overexpressed in neuroblastoma (NB) and retinoblastoma cell lines and tumors. NB patients with amplification of both DDX1 and MYCN have a poorer prognosis than patients with only MYCN gene amplification. DDXI has therefore oncogenic potential.
[0095] Co-treatment of MMC with BVDU reduces the overexpression of UBE2N and APEX by approximately one third. Modifications of UBE2N influence the resistance to DNA damage. APEX nuclease is a DNA repair enzyme. Blockade of the APEX
expression doubles the cell lysis and increases DNA breakages.
[00961 With respect to 3), BVDU induces DT-diaphorase (Example 3). The latter has two properties which are important for the chemotherapy. It activates, on the one hand, cytostatics from the class of quinones and, on the other hand, reduces non-specific toxic effects which are based on the production of reactive oxygen species.
[0097] Absence of the DT-D gene leads by reduced p53 and p73 expression to myeloid hyperplasia and correspondingly to reduced apoptosis rates. This is in accord with the observation that a multifactorial "multi-drug resistance" phenotype of tumor cells involves a reduction and no increase in DT-diaphorase expression. Interestingly, the DT-D
enzyme activity also stabilizes the lymphocyte populations. This effect could have an advantageous effect on the stabilization of the immune system of patients during chemotherapy.
[0098] Many cytostatics, such as e.g. DOX and MXA, disrupt the redox status and the mitochondrial respiration of the cancer cell. This leads to the production of reactive oxygen
[0093] The effect in the recovery phase after co-treatment with mytomycin C is particularly impressive. Here, the base analogue reduces the overexpression of the oncogene JUN-D to the control level (Example 2).
[00941 With respect to 2), base analogues such as BVDU block DDXl. DDX1 is co-amplified with MYCN and overexpressed in neuroblastoma (NB) and retinoblastoma cell lines and tumors. NB patients with amplification of both DDX1 and MYCN have a poorer prognosis than patients with only MYCN gene amplification. DDXI has therefore oncogenic potential.
[0095] Co-treatment of MMC with BVDU reduces the overexpression of UBE2N and APEX by approximately one third. Modifications of UBE2N influence the resistance to DNA damage. APEX nuclease is a DNA repair enzyme. Blockade of the APEX
expression doubles the cell lysis and increases DNA breakages.
[00961 With respect to 3), BVDU induces DT-diaphorase (Example 3). The latter has two properties which are important for the chemotherapy. It activates, on the one hand, cytostatics from the class of quinones and, on the other hand, reduces non-specific toxic effects which are based on the production of reactive oxygen species.
[0097] Absence of the DT-D gene leads by reduced p53 and p73 expression to myeloid hyperplasia and correspondingly to reduced apoptosis rates. This is in accord with the observation that a multifactorial "multi-drug resistance" phenotype of tumor cells involves a reduction and no increase in DT-diaphorase expression. Interestingly, the DT-D
enzyme activity also stabilizes the lymphocyte populations. This effect could have an advantageous effect on the stabilization of the immune system of patients during chemotherapy.
[0098] Many cytostatics, such as e.g. DOX and MXA, disrupt the redox status and the mitochondrial respiration of the cancer cell. This leads to the production of reactive oxygen
-24-species (ROS). Not only the cancer cell but also all other cells are affected by the sudden accumulation of ROS, as a result of which undesired side effects occur during chemotherapy.
[0099] DT-D inactivates ROS and thus protects cells from non-specific ROS and electrophilic attacks. As an index for this effect of BVDU on the reduction of undesired side effects during chemotherapy, the increase in weight of doxorubicin + BVDU-treated rats may be cited in Example 4. DOX treatment alone leads to weight losses because of the toxic side effects. It is certain that oniy the side effects (possibly the cardiotoxicity characteristic of DOX) are reduced by BVDU but not the toxic effects on the tumor.
[0100] With respect to 4), by altered expression of different enzymes in the recovery phase, the cytostatic effect is maintained also in the absence of a cytostatic. As can be seen in Example 5, the expression of eight genes is increased, that of six genes lowered.
[0101] The gene products influence the formation of microfilaments, differentiation, signal transduction and ATP generation.
EXAMPLES
[0102] The invention is further illustrated and described by way of the following non-limiting examples.
Example 1:
[0103] BVDU treatment increases the sensitivity of AH13r sarcoma cells to chemotherapy-induced apoptosis. This effect is maintained even after discontinuation of the cytostatic in the so-called recovery phase.
[0104] AH13r cells were subjected to increasing doses of the cytostatic mitomycin C
(MMC). BVDU, given alone, showed no toxic effect. MMC+BVDU treatment led, after three treatment cycles, to reduction in the cell number in comparison to treatment with MMC
alone. This inhibitory effect was maintained even after discontinuation of the cytostatic in the next cycle, in the so-called recovery phase. The cells without MMC and BVDU
continued to grow without inhibition. However, those which continued to receive BVDU
were greatly inhibited in their growth (see Fig. 1).
[0099] DT-D inactivates ROS and thus protects cells from non-specific ROS and electrophilic attacks. As an index for this effect of BVDU on the reduction of undesired side effects during chemotherapy, the increase in weight of doxorubicin + BVDU-treated rats may be cited in Example 4. DOX treatment alone leads to weight losses because of the toxic side effects. It is certain that oniy the side effects (possibly the cardiotoxicity characteristic of DOX) are reduced by BVDU but not the toxic effects on the tumor.
[0100] With respect to 4), by altered expression of different enzymes in the recovery phase, the cytostatic effect is maintained also in the absence of a cytostatic. As can be seen in Example 5, the expression of eight genes is increased, that of six genes lowered.
[0101] The gene products influence the formation of microfilaments, differentiation, signal transduction and ATP generation.
EXAMPLES
[0102] The invention is further illustrated and described by way of the following non-limiting examples.
Example 1:
[0103] BVDU treatment increases the sensitivity of AH13r sarcoma cells to chemotherapy-induced apoptosis. This effect is maintained even after discontinuation of the cytostatic in the so-called recovery phase.
[0104] AH13r cells were subjected to increasing doses of the cytostatic mitomycin C
(MMC). BVDU, given alone, showed no toxic effect. MMC+BVDU treatment led, after three treatment cycles, to reduction in the cell number in comparison to treatment with MMC
alone. This inhibitory effect was maintained even after discontinuation of the cytostatic in the next cycle, in the so-called recovery phase. The cells without MMC and BVDU
continued to grow without inhibition. However, those which continued to receive BVDU
were greatly inhibited in their growth (see Fig. 1).
-25-[0105] Corresponding results were achieved with methotrexate (MTX), doxorubicin (DOX) and mitoxantrone (MXA) (see Fig. 2).
[0106] The indication that the reduction in cell number is based on apoptosis, was detected by means of Hoechst 33258/propidium iodide (Hopi) double coloration.
Example 2:
[0107] Different "survival pathways" were tested by means of Western Blot analysis. The analyses were implemented according to standard methods, as is described in Sambrook et al., 2001, Molecular Cloning (3d ed.). Antibody dilutions: P-STAT3 (cell signaling) 1: 500, JUN-D (Santa Cruz, California) 1: 1,000. The upper of the two JUN-D bands shows the "full length isoform" and the lower band the "truncated isoform" which is 48 amino acids shorter. Both isoforms can activate the transcription, but the "full length"
variant is more effective than the "truncated" isoform (cf. Fig. 3).
[0108] The densitometrically determined content of oncogene proteins JUN-D and was reduced by a quarter or two thirds after IbOX treatment in the recovery phase (r =
recovery phase}. In the "recovery" only BVDU is given, no cytostatic.
[0109] A corresponding result was achieved in the tests with mitomycin C (MMC) (see Fig. 4).
[0110] In the test with mitomycin C (MMC), BVDU, given in the "recovery", effected a complete inhibition of the MMC induced JUN-D overexpression to the control level.
Example 3:
[0111] The measurement of the DT-diaphorase (DT-D) was effected as a dicoumarol-inhibitable NAD(P)H: dichlorophenol indophenol reductase, as described in Hodnick et al., Anal. Biochem 252(1), 1997, 165 - 168 (incorporated by reference herein in its entirety).
Extracts were tested of a similar number of cells which had been treated with DOX +/-BVDU for DT-D activity. Cells treated with BVDU showed an approximately threefold DT-D activity relative to the cells from the control group or from the group of cells treated solely with DOX (see Fig. 5).
[0106] The indication that the reduction in cell number is based on apoptosis, was detected by means of Hoechst 33258/propidium iodide (Hopi) double coloration.
Example 2:
[0107] Different "survival pathways" were tested by means of Western Blot analysis. The analyses were implemented according to standard methods, as is described in Sambrook et al., 2001, Molecular Cloning (3d ed.). Antibody dilutions: P-STAT3 (cell signaling) 1: 500, JUN-D (Santa Cruz, California) 1: 1,000. The upper of the two JUN-D bands shows the "full length isoform" and the lower band the "truncated isoform" which is 48 amino acids shorter. Both isoforms can activate the transcription, but the "full length"
variant is more effective than the "truncated" isoform (cf. Fig. 3).
[0108] The densitometrically determined content of oncogene proteins JUN-D and was reduced by a quarter or two thirds after IbOX treatment in the recovery phase (r =
recovery phase}. In the "recovery" only BVDU is given, no cytostatic.
[0109] A corresponding result was achieved in the tests with mitomycin C (MMC) (see Fig. 4).
[0110] In the test with mitomycin C (MMC), BVDU, given in the "recovery", effected a complete inhibition of the MMC induced JUN-D overexpression to the control level.
Example 3:
[0111] The measurement of the DT-diaphorase (DT-D) was effected as a dicoumarol-inhibitable NAD(P)H: dichlorophenol indophenol reductase, as described in Hodnick et al., Anal. Biochem 252(1), 1997, 165 - 168 (incorporated by reference herein in its entirety).
Extracts were tested of a similar number of cells which had been treated with DOX +/-BVDU for DT-D activity. Cells treated with BVDU showed an approximately threefold DT-D activity relative to the cells from the control group or from the group of cells treated solely with DOX (see Fig. 5).
- 26 -[0112] Corresponding results were achieved with mitoxantrone (MXA) and methotrexate (MTX). BVDU alone increases the DT-D activity constantly, but in part only weakly.
[0113] The results with methotrexate (MTX) and human K562 tumor cells are illustrated in Fig. 6, in which "MB" means "MTX and BVDU." Passage means dilution and conversion of the cells for further growth. The relative DT-D activity is illustrated on the Y axis.
Example 4:
[0114] The reduction in toxic side effects of doxorubicin (DOX) was able to be shown in the test with rats (see Table 3). SD rats were treated with dimethybenzanthracene (DMBA).
The consequently induced tumors were inhibited in their growth by DOX
treatment (1 mg/kg). During the treatment and one day after each treatment, i.e. in the recovery phase, the animals obtained respectively 15 mg/kg BVDU. The recovery phase in vivo was 6xone day.
Table 3 Average of the Relative tumor Relative animal Relative tumor Relative animal data from 5 - 8 size weight size weight rats Day 1 Day 1 Day 16 Day 16 Control 1 0 6 +7%
DOX alone 1 0 1.5 - 7%
DOX + BVDU 1 0 1 +7%
Example 5:
[0115] Listing of the proteins influenced by the treatment with base analogues and mitomycin C. The results of the implementation of a two- dimensional gel electrophoresis are compiled in the following Table 4.
Table 4 Protein DMSO control BVDU alone DEAD/H BOX 1; DDX1 0.88 0.332 MMC alone MMC + BVDU
MALATE-DEHYDROGENASE, SOLUBLE; MDH1 0.418 1.359 MYOSIN, HEAVY CHAIN 1, NORMAL SIMILARITY, ADULT; 0.182 0.588 MYH I
UBIQUITIN-CONJUGATING ENZYME E2N; UBE2N 0.669 0.178
[0113] The results with methotrexate (MTX) and human K562 tumor cells are illustrated in Fig. 6, in which "MB" means "MTX and BVDU." Passage means dilution and conversion of the cells for further growth. The relative DT-D activity is illustrated on the Y axis.
Example 4:
[0114] The reduction in toxic side effects of doxorubicin (DOX) was able to be shown in the test with rats (see Table 3). SD rats were treated with dimethybenzanthracene (DMBA).
The consequently induced tumors were inhibited in their growth by DOX
treatment (1 mg/kg). During the treatment and one day after each treatment, i.e. in the recovery phase, the animals obtained respectively 15 mg/kg BVDU. The recovery phase in vivo was 6xone day.
Table 3 Average of the Relative tumor Relative animal Relative tumor Relative animal data from 5 - 8 size weight size weight rats Day 1 Day 1 Day 16 Day 16 Control 1 0 6 +7%
DOX alone 1 0 1.5 - 7%
DOX + BVDU 1 0 1 +7%
Example 5:
[0115] Listing of the proteins influenced by the treatment with base analogues and mitomycin C. The results of the implementation of a two- dimensional gel electrophoresis are compiled in the following Table 4.
Table 4 Protein DMSO control BVDU alone DEAD/H BOX 1; DDX1 0.88 0.332 MMC alone MMC + BVDU
MALATE-DEHYDROGENASE, SOLUBLE; MDH1 0.418 1.359 MYOSIN, HEAVY CHAIN 1, NORMAL SIMILARITY, ADULT; 0.182 0.588 MYH I
UBIQUITIN-CONJUGATING ENZYME E2N; UBE2N 0.669 0.178
-27-APURINIC ENDONUCLEASE; APE; APE1; APEX 0.363 0.14 MMC "recovery", MMC + BVDU
further cultivation "recovery", without MMC and further treatment by BVDU BVDU alone PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, 0.219 0.619 ISOFORM 1B, ALPHA SUB-UNIT; PAFAHIBI
U5 snRNP-SPECIFIC PROTEIN, 116-KD 0.2 0.523 HAEMOGLOBIN-BETA LOCUS; HBB 0.088 0.502 HAEMOGLOBIN-ALPHA LOCUS 1; HBAI 0.054 0.316 ACTIN, BETA; ACTB 0.163 0.451 Similar to BETA-ACTIN 0.096 0.357 ACTIN similar 0.112 0.398 TROPOMODULIN 2; TMOD2 0.095 0.28 SUCCINATE-DEHYDROGENASE COMPLEX, SUB-UNIT A, 0.255 absent FLAVOPROTEIN; SDHA
PYRUVATE-DEHYDROGENASE COMPLEX, El-ALPHA 1.751 0,533 POLYPEPTIDE 1; PDHA1 TUBULIN, BETA-5 4.705 1.553 POLY(rC)-BINDING PROTEIN 2; PCBP2 0.912 0.234 MALATE-ENZYME 2; ME2 0.972 0.322 Mini-chromosome preservation inadequate 7; MITOTIN, CELL 0.374 0.119 CLASS CYCLE SIMILAR 1; CDCLI
Example 6:
[0116] Pilot study: 13 Patients (mean age 61, 69% males, 4 stage III, 9 stage IV) with advanced pancreatic adenocarcinoma were treated with i.v. 1.000 mg/m2 GEM over 30 min on days 1 and 15 of a 28-day schedule. CIS was administered at 50 mg/m2. BVDU
treatment took place on the same day and for four days after chemotherapy in the recovery phase (each four 125 mg tablets per day, resulting in a total dose of 6.000 mg per treatment cycle). As control, data were used of patients of a preceding study which were treated with GEM and CIS, but not with BVDU. With the intention to obtain a control group with a similar proportion of stage IV and stage III diseases as the 13 patients of the pilot study, 22 (6 stage III, 15 stage IV) of 96 patients were selected from the Heinemann study by random generator.
101171 BVDU co-treatment enhanced remissions, survival and time to progression (TTP).
77% of the patients lived or have lived longer than one year, and 23% live more than two years. Median survival was 447 days, TTP 280 days, and the response rate 33%.
further cultivation "recovery", without MMC and further treatment by BVDU BVDU alone PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, 0.219 0.619 ISOFORM 1B, ALPHA SUB-UNIT; PAFAHIBI
U5 snRNP-SPECIFIC PROTEIN, 116-KD 0.2 0.523 HAEMOGLOBIN-BETA LOCUS; HBB 0.088 0.502 HAEMOGLOBIN-ALPHA LOCUS 1; HBAI 0.054 0.316 ACTIN, BETA; ACTB 0.163 0.451 Similar to BETA-ACTIN 0.096 0.357 ACTIN similar 0.112 0.398 TROPOMODULIN 2; TMOD2 0.095 0.28 SUCCINATE-DEHYDROGENASE COMPLEX, SUB-UNIT A, 0.255 absent FLAVOPROTEIN; SDHA
PYRUVATE-DEHYDROGENASE COMPLEX, El-ALPHA 1.751 0,533 POLYPEPTIDE 1; PDHA1 TUBULIN, BETA-5 4.705 1.553 POLY(rC)-BINDING PROTEIN 2; PCBP2 0.912 0.234 MALATE-ENZYME 2; ME2 0.972 0.322 Mini-chromosome preservation inadequate 7; MITOTIN, CELL 0.374 0.119 CLASS CYCLE SIMILAR 1; CDCLI
Example 6:
[0116] Pilot study: 13 Patients (mean age 61, 69% males, 4 stage III, 9 stage IV) with advanced pancreatic adenocarcinoma were treated with i.v. 1.000 mg/m2 GEM over 30 min on days 1 and 15 of a 28-day schedule. CIS was administered at 50 mg/m2. BVDU
treatment took place on the same day and for four days after chemotherapy in the recovery phase (each four 125 mg tablets per day, resulting in a total dose of 6.000 mg per treatment cycle). As control, data were used of patients of a preceding study which were treated with GEM and CIS, but not with BVDU. With the intention to obtain a control group with a similar proportion of stage IV and stage III diseases as the 13 patients of the pilot study, 22 (6 stage III, 15 stage IV) of 96 patients were selected from the Heinemann study by random generator.
101171 BVDU co-treatment enhanced remissions, survival and time to progression (TTP).
77% of the patients lived or have lived longer than one year, and 23% live more than two years. Median survival was 447 days, TTP 280 days, and the response rate 33%.
-28-[0118] Dose finding study: 22 Patients with advanced pancreatic adenocarcinoma were eligible for treatment in this single arm study. The mean age was 60 years and 73% of patients were males. One patient without progressive disease was excluded from the study for withdrawal of consent after the first cycle. Of the 21 patients left, 15 were in stage IV and 6 in stage III. BVDU was administered in a combination with GEM. On day 1, on day 8 and on day 15 of each 28-day cycle, BVDU was given together with GEM. On days 2-4, on days 8-11, and on days 15-18 of a 28-day cycle, BVDU was given alone in the recovery phase.
[0119] The starting dose of BVDU was 4 x 125 mg/day (total dose of 6,000 mg per treatment cycle) together with a fixed dose of GEM (1,000 mg/m'). Subsequent total doses of BVDU per cycle were 7,500 mg, 9,000 mg, 10,500 mg, and 12,000 mg again in four patients per cohort. Dosage levels were administered as follows: First dose level.= The starting dose of BVDU was 4 x 125 mg daily given at approximately 08:00 a.m.
(1 x 125 mg BVDU), 12:00 a.m. (I x 125 mg BVDU), 04:00 p.m. (1 x 125 mg BVDU), and 08:00 p.m. (1 x 125 mg BVDU). These doses were administered on days 1 to 4, days 8 to 11 and days 15 to 18; Second dose level: 1 x 250 mg + 3 x 125 mg daily; Third dose level: 2 x 250 mg + 2 x 125 mg daily; Forth dose level: 3 x 250 mg + 1 x 125 mg daily; and, Fifth dose level: 4 x 250 mg daily.
[0120] Approximately 1 hour after the 08:00 a.m. BVDU-administration on day 1, day 8 and day 15 of a cycle, the GEM infusion started and GEM was infused for 30 minutes.
[0121] Patients were treated as long as there was no indication of tumor progression. As control group served a group of 21 patients (Heinemann study) treated with GEM
alone, 15 being in stage IV and 6 in stage III of disease, and treated with GEM alone.
[0122] Analysis of the concentrations of GEM and BVDU (BVDU) as well as analysis of the concentrations of BVU ((E)-5-(2-bromovinyl) uracil, degradation product of BVDU) in plasma samples: 0.5 ml of plasma spiked with about 0.5 g of 4-Propyl-2-thiouracil (PTU) as internal standard was extracted with 2.5 ml of methanol-acetonitrile (v/v, 1:9) by vigorous mixing for about 1 min. After centrifugation the supernatant was transferred to a beaker and evaporated to dryness at 50 C under a gentle stream of nitrogen. The residue was dissolved in 1 ml of the solution used as mobile phase by 10 min treatment in an ultrasonic bath. After centrifugation the clear supernatant was used for HPLC-analysis. The concentrations of
[0119] The starting dose of BVDU was 4 x 125 mg/day (total dose of 6,000 mg per treatment cycle) together with a fixed dose of GEM (1,000 mg/m'). Subsequent total doses of BVDU per cycle were 7,500 mg, 9,000 mg, 10,500 mg, and 12,000 mg again in four patients per cohort. Dosage levels were administered as follows: First dose level.= The starting dose of BVDU was 4 x 125 mg daily given at approximately 08:00 a.m.
(1 x 125 mg BVDU), 12:00 a.m. (I x 125 mg BVDU), 04:00 p.m. (1 x 125 mg BVDU), and 08:00 p.m. (1 x 125 mg BVDU). These doses were administered on days 1 to 4, days 8 to 11 and days 15 to 18; Second dose level: 1 x 250 mg + 3 x 125 mg daily; Third dose level: 2 x 250 mg + 2 x 125 mg daily; Forth dose level: 3 x 250 mg + 1 x 125 mg daily; and, Fifth dose level: 4 x 250 mg daily.
[0120] Approximately 1 hour after the 08:00 a.m. BVDU-administration on day 1, day 8 and day 15 of a cycle, the GEM infusion started and GEM was infused for 30 minutes.
[0121] Patients were treated as long as there was no indication of tumor progression. As control group served a group of 21 patients (Heinemann study) treated with GEM
alone, 15 being in stage IV and 6 in stage III of disease, and treated with GEM alone.
[0122] Analysis of the concentrations of GEM and BVDU (BVDU) as well as analysis of the concentrations of BVU ((E)-5-(2-bromovinyl) uracil, degradation product of BVDU) in plasma samples: 0.5 ml of plasma spiked with about 0.5 g of 4-Propyl-2-thiouracil (PTU) as internal standard was extracted with 2.5 ml of methanol-acetonitrile (v/v, 1:9) by vigorous mixing for about 1 min. After centrifugation the supernatant was transferred to a beaker and evaporated to dryness at 50 C under a gentle stream of nitrogen. The residue was dissolved in 1 ml of the solution used as mobile phase by 10 min treatment in an ultrasonic bath. After centrifugation the clear supernatant was used for HPLC-analysis. The concentrations of
-29-GEM and BVDU were calculated using a calibration curve with the respective standard substances. The concentrations of BVU were calculated using the calibration curve of BVDU and the determined response factor. Limits of detection: BVDU 20 ng/ml plasma;
GEM 30 ng/ml plasma. Limits of quantification: BVDU 60 ng/ml plasma; GEM 100 ng/ml plasma.
[0123] Evaluation: Efficacy was measured by overall survival, objective tumor response rate (ORR, according to WHO criteria in the pilot study and RECIST criteria in the dose finding study) and time to progression (TTP) from the first administration onwards. Serum CA19-9 levels were measured at the start and end of each treatment cycle.
Safety was evaluated according to NCI-CTC scale.
[0124] Evaluation of Progression: Patients were evaluated every five weeks.
[0125] Statistical Methods: Survival curves were generated using the Kaplan-Meier method; survival distributions were compared by the log-rank test (Cox-Mantel), and median survival by the Box and Whisker plot.
[0126] Clinical effects of BVDU in patients treated with GEM+CIS+BVDU.= All patients showed at least a stable disease, and 33% of them remissions according to WHO
criteria (Table 5). The course of disease was followed by monitoring tumor marker CA19-9. The highest normal value is 35. In 75% of the cases, the tumor marker responded to the co-treatment (total dose of BVDU per cycle was 6.000mg) and in several cases to the second line therapy without BVDU indicating that the tumors had not acquired resistance (Figure 7).
Table 5 Patients treated with GEM+CIS+BVDU
Pt age stage Sur- Remissions TTP Cycle CA19-9 before the no. vival sonography (days) BVDU first and after the (days) and CT 6th or earlier cycle 1 52 TxNxM1G2 447 partial 279 6 10621 / 155 2 59 TxNxM1G2 271 lung 238 5 9372 / 7678 metastases 3 68 TxNxMOG4 549 SD 327 1 53 / 25
GEM 30 ng/ml plasma. Limits of quantification: BVDU 60 ng/ml plasma; GEM 100 ng/ml plasma.
[0123] Evaluation: Efficacy was measured by overall survival, objective tumor response rate (ORR, according to WHO criteria in the pilot study and RECIST criteria in the dose finding study) and time to progression (TTP) from the first administration onwards. Serum CA19-9 levels were measured at the start and end of each treatment cycle.
Safety was evaluated according to NCI-CTC scale.
[0124] Evaluation of Progression: Patients were evaluated every five weeks.
[0125] Statistical Methods: Survival curves were generated using the Kaplan-Meier method; survival distributions were compared by the log-rank test (Cox-Mantel), and median survival by the Box and Whisker plot.
[0126] Clinical effects of BVDU in patients treated with GEM+CIS+BVDU.= All patients showed at least a stable disease, and 33% of them remissions according to WHO
criteria (Table 5). The course of disease was followed by monitoring tumor marker CA19-9. The highest normal value is 35. In 75% of the cases, the tumor marker responded to the co-treatment (total dose of BVDU per cycle was 6.000mg) and in several cases to the second line therapy without BVDU indicating that the tumors had not acquired resistance (Figure 7).
Table 5 Patients treated with GEM+CIS+BVDU
Pt age stage Sur- Remissions TTP Cycle CA19-9 before the no. vival sonography (days) BVDU first and after the (days) and CT 6th or earlier cycle 1 52 TxNxM1G2 447 partial 279 6 10621 / 155 2 59 TxNxM1G2 271 lung 238 5 9372 / 7678 metastases 3 68 TxNxMOG4 549 SD 327 1 53 / 25
-30-4 59 T4NxM1G2 >886 Complete: liver 735 4 1709 / 22 metastases 53 T4NxM1G2 80 SD 70 3 84 / 55101 6 63 TxNxMxG2 >880 partial 281 6 23362 / 21 7 63 T2NOM1Gx 407 minor 247 6 9436 / 117 8 64 TxNxM1G1 420 SD 331 1 1101 / 110 9 66 T3N1MOG2 447 partial 184 4 125 / 131 70 TxNxM1Gx 378 SD 285 6 739219 / 285 11 75 T4NxM1Gx 196 SD 102 3 7147 / 3734 12 41 T4NxMxG2 >789 Partial >789 4 332 / 6 (complete after surgery) 13 63 TxNxM1Gx 463 SD n.d. 2 n.d.
61 4 x III, 9 x >478 33 % >322 4(1-6) 75 % PR or CR
IV
[0127] In the BVDU-treatment group, median survival (447 days, p=0.006) and time to progression (280 days, p=0.004) were significantly higher compared to the control group (Figure 8). Ten of 13 patients (nine in stage IV and four in stage III) lived or live longer than one year after first treatment, and three of them have lived for more than two years by now.
The patient characteristics are summarized in Table 5. In the control group, median survival was 186 days and median time to progression 104 days (Figure 8).
[0128] Clinical effects of BVDU in patients treated with GEM+BVDU: Nineteen of patients showed a stable disease, but only one a remission according to RECIST
criteria (Table 6). The total doses of BVDU per cycle were 6,000, 7,500 mg, 9,000 mg, 10,500 mg, and 12,000 mg in four patients per group. The results are based on interim data from an ongoing study and patients without progression are still being treated. The data on the survival status show that 15 of 18 (83%) lived or have lived for half a year or longer, and 3 of 9 (33%) for longer than one year. The data of time to progression status show that 9 of 18 (50%) were progression free half a year or longer, and 2 of 9 (22%) one year or longer. The patients being less than half a year, respectively one year in the study were neglected in this calculation. In the control group 8 of 20 patients (40%) lived half a year or longer, and 3 of (15%) one year or longer. Four of 20 (20%) had a TTP half a year or longer.
One year
61 4 x III, 9 x >478 33 % >322 4(1-6) 75 % PR or CR
IV
[0127] In the BVDU-treatment group, median survival (447 days, p=0.006) and time to progression (280 days, p=0.004) were significantly higher compared to the control group (Figure 8). Ten of 13 patients (nine in stage IV and four in stage III) lived or live longer than one year after first treatment, and three of them have lived for more than two years by now.
The patient characteristics are summarized in Table 5. In the control group, median survival was 186 days and median time to progression 104 days (Figure 8).
[0128] Clinical effects of BVDU in patients treated with GEM+BVDU: Nineteen of patients showed a stable disease, but only one a remission according to RECIST
criteria (Table 6). The total doses of BVDU per cycle were 6,000, 7,500 mg, 9,000 mg, 10,500 mg, and 12,000 mg in four patients per group. The results are based on interim data from an ongoing study and patients without progression are still being treated. The data on the survival status show that 15 of 18 (83%) lived or have lived for half a year or longer, and 3 of 9 (33%) for longer than one year. The data of time to progression status show that 9 of 18 (50%) were progression free half a year or longer, and 2 of 9 (22%) one year or longer. The patients being less than half a year, respectively one year in the study were neglected in this calculation. In the control group 8 of 20 patients (40%) lived half a year or longer, and 3 of (15%) one year or longer. Four of 20 (20%) had a TTP half a year or longer.
One year
-31-TTP was not observed at all. For the analyses according to Kaplan-Meier all BVDU dose groups were combined, which included 21 enrolled patients (Figure 9). The results are similar but not identical to those of the pilot study with GEM+CIS+BVDU
(Figure 8). To date, adverse events are consistent with those observed with GEM or the underlying disease.
Table 6 Patients treated with GEM+BVDU
Pt Age Stage Survival Remissions TTP Cycle CA19-9: highest No (days) sonography days BVDU and lowest level and CT
6,000 m BVDU per cycle 101 60 T4NxM1G2 189 SD (4,000, 119 5 902/142 3x 6,000, 2,000 mg BVDU) 102 68 T3N1MxG3 228 SD 139 6 144/10 104 72 T4N1M1G3 178 SD 140 6 12,465/7,229 7,500 mg BVDU per cycle 105 41 T3NOM1G2 >424 CR >424 8 6/3 107 73 T3NOM1G3 82 SD (20,500, 2,500 64 3 19/6 m BVDU
108 62 T4NxM1G2 309 SD 217 7 1,875/494 201 69 T4N1M1Gx >366 SD >366 8+ 1,640/698 9,000 m BVDU per c cle 109 67 T4N1MOGx >326 SD (9,000, 8,500, >326 6 26/18 4x7.500 mg BVDU) 202 69 T4N1M1G3 >298 SD 255 6 1,368/490 110 59 TxNxM1G3 137 SD (3x9,000, 6,000 94 4 79,200/ 22,1589 m g BVDU) 111 56 T4N1MOGx >290 SD >290 8+ 3,721/190 10,500 m BVDU per cycle 112 41 T3NOM1Gx 66 SD 66 2 14,000 /*
301 70 T4N1M1G1 >255 SD (2x10,500, >255 6+ 556/92 10,000, 3x9,000 mg BVDU) (302) (64) T3NOMxG3 Excluded: without any progressive [1] (9,564/7,458) disease cycle 2 not completed 203 68 TxNOM1Gx >248 SD (10,500, 9,5oo, 229 6 7,709/2,973 9,000, 7,500) 204 62 T2N1M1G3 >240 SD (2x10,500, 223 5 2,881/1,797 9,125, 9,000 mg BVDU) 12,000 mg BVDU per cycle 303 62 T3N1MOGx >207 SD (11,500, 9,500 46 2 148/357 mg BVDU) 205 39 T4NOM1G2 >171 SD (12,000, 119 5 63,801/8,389 11,750, 12,000 mg BVDU) 207 67 T4NOM1G3 >109 SD 65 2+ 218 * This value could not be determined because patient survival was too short.
(Figure 8). To date, adverse events are consistent with those observed with GEM or the underlying disease.
Table 6 Patients treated with GEM+BVDU
Pt Age Stage Survival Remissions TTP Cycle CA19-9: highest No (days) sonography days BVDU and lowest level and CT
6,000 m BVDU per cycle 101 60 T4NxM1G2 189 SD (4,000, 119 5 902/142 3x 6,000, 2,000 mg BVDU) 102 68 T3N1MxG3 228 SD 139 6 144/10 104 72 T4N1M1G3 178 SD 140 6 12,465/7,229 7,500 mg BVDU per cycle 105 41 T3NOM1G2 >424 CR >424 8 6/3 107 73 T3NOM1G3 82 SD (20,500, 2,500 64 3 19/6 m BVDU
108 62 T4NxM1G2 309 SD 217 7 1,875/494 201 69 T4N1M1Gx >366 SD >366 8+ 1,640/698 9,000 m BVDU per c cle 109 67 T4N1MOGx >326 SD (9,000, 8,500, >326 6 26/18 4x7.500 mg BVDU) 202 69 T4N1M1G3 >298 SD 255 6 1,368/490 110 59 TxNxM1G3 137 SD (3x9,000, 6,000 94 4 79,200/ 22,1589 m g BVDU) 111 56 T4N1MOGx >290 SD >290 8+ 3,721/190 10,500 m BVDU per cycle 112 41 T3NOM1Gx 66 SD 66 2 14,000 /*
301 70 T4N1M1G1 >255 SD (2x10,500, >255 6+ 556/92 10,000, 3x9,000 mg BVDU) (302) (64) T3NOMxG3 Excluded: without any progressive [1] (9,564/7,458) disease cycle 2 not completed 203 68 TxNOM1Gx >248 SD (10,500, 9,5oo, 229 6 7,709/2,973 9,000, 7,500) 204 62 T2N1M1G3 >240 SD (2x10,500, 223 5 2,881/1,797 9,125, 9,000 mg BVDU) 12,000 mg BVDU per cycle 303 62 T3N1MOGx >207 SD (11,500, 9,500 46 2 148/357 mg BVDU) 205 39 T4NOM1G2 >171 SD (12,000, 119 5 63,801/8,389 11,750, 12,000 mg BVDU) 207 67 T4NOM1G3 >109 SD 65 2+ 218 * This value could not be determined because patient survival was too short.
- 32 -[0129] Pharmacokinetic Results BVDU: All measurements were performed within 9 hours. Therefore, only the first three intakes of BVDU-tablets were relevant in this context, and as consequence, in dose groups four and five the intake of tablets was identical. When the dose was doubled from 125 mg to 250 mg, the mean maximum BVDU
concentration in plasma increased fivefold from 290 ( 152) ng/ml to 1549 ( 1058) ng/ml (Figure 10).
[0130] BVU: The mean maximum BVU concentration increased nearly proportional with the dose of BVDU from 1525 ( 1012) ng/ml to 4637 ( 1353) ng/mi.
[0131] GEM: The maximum concentrations were measured immediately after completion of the 30 min infusion. The maximum values varied between 3185 and 29040 ng/ml. BVDU
was given half an hour before GEM and the second time 4 hours later. At this time GEM was not detectable any more. Therefore, an influence on GEM concentration by BVDU
could only be exerted by the first intake of tablets. For this reason only the first two doses of BVDU (125 and 250 mg) can be compared. The GEM maximum values appear to rise with increase of the BVDU dose but the large degree of variability between individual patients should be considered (Figure 10).
Example 7:
[0132] Ten SD-rats per treatment group were given a single s.c. injection of ascites Yoshida AH13r hepatoma cells. Five to 7 days after tumor application, the growth of the resulting tumors (at the injection site) was suppressed by i.p. treatment of the animals with cisplatin, doxorubicin or cyclophosphamide, or by additional oral treatment with 15 mg/kg BVDU (15 times within 3 weeks).
[0133] As seen in Fig. 12, BVDU, given alone, exerts no influence on the growths of rat tumors. On the contrary, the tumors seem to grow rather faster than slower than those without treatment.
[0134] The result of chemotherapy without "recovery" effect is shown in the treatment schedule of Figure 13a. In this instance, BVDU is given simultaneously with cisplatin (CIS):
[0135] Fig. 14 shows the effect of BVDU if given only at the same day as the cytotoxic drug, and indicates that if BVDU is given only on the same day as the cytotoxic drug, its
concentration in plasma increased fivefold from 290 ( 152) ng/ml to 1549 ( 1058) ng/ml (Figure 10).
[0130] BVU: The mean maximum BVU concentration increased nearly proportional with the dose of BVDU from 1525 ( 1012) ng/ml to 4637 ( 1353) ng/mi.
[0131] GEM: The maximum concentrations were measured immediately after completion of the 30 min infusion. The maximum values varied between 3185 and 29040 ng/ml. BVDU
was given half an hour before GEM and the second time 4 hours later. At this time GEM was not detectable any more. Therefore, an influence on GEM concentration by BVDU
could only be exerted by the first intake of tablets. For this reason only the first two doses of BVDU (125 and 250 mg) can be compared. The GEM maximum values appear to rise with increase of the BVDU dose but the large degree of variability between individual patients should be considered (Figure 10).
Example 7:
[0132] Ten SD-rats per treatment group were given a single s.c. injection of ascites Yoshida AH13r hepatoma cells. Five to 7 days after tumor application, the growth of the resulting tumors (at the injection site) was suppressed by i.p. treatment of the animals with cisplatin, doxorubicin or cyclophosphamide, or by additional oral treatment with 15 mg/kg BVDU (15 times within 3 weeks).
[0133] As seen in Fig. 12, BVDU, given alone, exerts no influence on the growths of rat tumors. On the contrary, the tumors seem to grow rather faster than slower than those without treatment.
[0134] The result of chemotherapy without "recovery" effect is shown in the treatment schedule of Figure 13a. In this instance, BVDU is given simultaneously with cisplatin (CIS):
[0135] Fig. 14 shows the effect of BVDU if given only at the same day as the cytotoxic drug, and indicates that if BVDU is given only on the same day as the cytotoxic drug, its
- 33 -effect is only weak. In these experiments the dose was very high, i.e. 50 mg/kg. This is much more than the standard dose of 15 mg/kg.
[0136] As shown in Fig. 13b, doxorubicin may be given to provide a recovery phase in vivo of 6 x one day. Fig. 15 shows the effect of this treatment schedule of BVDU in the "recovery" phase. BVDU, if given rotatory alone or in combination with DOX in the "recovery" phase, has a strong effect. The effect of BVDU is very strong, even if the recovery phase is just only one day.
[0137] The recovery phase can be enhanced to 4 x 3 or 2 days, obtaining a treatment schedule such as shown in Fig. 13c. The effect of this treatment schedule is shown in Fig. 16, showing that the effect of BVDU is very strong, especially when compared to the very weak effect if the treatment is restricted to an exclusively simultaneous administration of CIS+BVDU (e.g., Fig. 14).
[0138] An elongation of the treatment in the recovery phase is preferred with cyclophosphamide (Fig. 13d), as cyclophosphamide has sufficient long term effects. The effect of 14 days treatment with BVDU in the "recovery" phase is shown in Fig.
17, indicating that BVDU, given 15 times alone in the recovery phase and only one time at the beginning of treatment together with cyclophosphamide, has a strong effect.
[0139] Cyclophosphamide gives the best example for the effect of BVDU in the recovery phase. In summary, BVDU allows different treatment schedules for different cytotoxic drugs. The recovery treatment phase can vary from 6 x one day to 1 x 14 days.
[0140] The practical application of these results of animal experiments can be seen in the clinical studies of patients with pancreatic cancer.
[0141] Although the present invention has been described in considerable detail with regard to certain versions thereof, other versions are possible, and alterations, permutations, and equivalents of the version shown will become apparent to those skilled in the art upon a reading of the specification and study of the drawings. Also, the various features of the versions herein can be combined in various ways to provide additional versions of the present invention. Furthermore, certain terminology has been used for the purposes of descriptive
[0136] As shown in Fig. 13b, doxorubicin may be given to provide a recovery phase in vivo of 6 x one day. Fig. 15 shows the effect of this treatment schedule of BVDU in the "recovery" phase. BVDU, if given rotatory alone or in combination with DOX in the "recovery" phase, has a strong effect. The effect of BVDU is very strong, even if the recovery phase is just only one day.
[0137] The recovery phase can be enhanced to 4 x 3 or 2 days, obtaining a treatment schedule such as shown in Fig. 13c. The effect of this treatment schedule is shown in Fig. 16, showing that the effect of BVDU is very strong, especially when compared to the very weak effect if the treatment is restricted to an exclusively simultaneous administration of CIS+BVDU (e.g., Fig. 14).
[0138] An elongation of the treatment in the recovery phase is preferred with cyclophosphamide (Fig. 13d), as cyclophosphamide has sufficient long term effects. The effect of 14 days treatment with BVDU in the "recovery" phase is shown in Fig.
17, indicating that BVDU, given 15 times alone in the recovery phase and only one time at the beginning of treatment together with cyclophosphamide, has a strong effect.
[0139] Cyclophosphamide gives the best example for the effect of BVDU in the recovery phase. In summary, BVDU allows different treatment schedules for different cytotoxic drugs. The recovery treatment phase can vary from 6 x one day to 1 x 14 days.
[0140] The practical application of these results of animal experiments can be seen in the clinical studies of patients with pancreatic cancer.
[0141] Although the present invention has been described in considerable detail with regard to certain versions thereof, other versions are possible, and alterations, permutations, and equivalents of the version shown will become apparent to those skilled in the art upon a reading of the specification and study of the drawings. Also, the various features of the versions herein can be combined in various ways to provide additional versions of the present invention. Furthermore, certain terminology has been used for the purposes of descriptive
-34-clarity, and not to limit the present invention. Therefore, any appended claims should not be limited to the description of the preferred versions contained herein and should include all such alterations, permutations, and equivalents as fall within the true spirit and scope of the present invention.
[0142] Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations, and other parameters without departing from the scope of the invention or any embodiments thereof.
[0142] Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations, and other parameters without departing from the scope of the invention or any embodiments thereof.
-35-
Claims (54)
1. A method for treating a cancer treatable with gemcitabine comprising administering to a patient in need thereof a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase and a recovery phase.
2. The method of claim 1 wherein the cancer treatable with gemcitabine includes pancreatic cancer.
3. The method of claim 1 comprising administering the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the chemotherapy phase.
4. The method of claim 3 wherein the chemotherapy phase is about 1 to 5 days
5. The method of claim 1 comprising administering the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the recovery phase.
6 The method of claim 5 wherein the recovery phase is about 1 to 10 days
7 The method of claim 5 further comprising administering a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, during the chemotherapy phase.
8. The method of claim 7 wherein the chemotherapy phase is about 1 to 30 days.
9. The method of claim 8 wherein the recovery phase is about 1 to 30 days.
10. The method of claim 9 further comprising a rest phase during which no cytotoxic agent or 5-substituted nucleoside is administered.
11. The method of claim 10 wherein the rest phase is about 8 to 60 days.
12. The method of claim 1 wherein the cytotoxic composition comprises a second cytotoxic agent other than gemcitabine.
13. The method of claim 12 wherein the second cytotoxic agent comprises a platinum compound.
14. The method of claim 13 wherein the second cytotoxic agent comprises cisplatin.
15. The method of claim 1 wherein the 5-substituted nucleoside, prodrug, or salt thereof, or combination of two or more thereof, comprises BVDU, or a prodrug, or salt thereof,.
16. The method of claim 15 wherein the patient is administered the BVDU, prodrug, or salt thereof during the chemotherapy phase, and attains a BVDU blood level of about 0.02 to 50 µg/ml during the chemotherapy phase.
17. The method of claim 15 wherein the patient is administered the BVDU, prodrug, or salt thereof, during the chemotherapy phase, and attains a BVDU AUC of at least about 0.5 µg.cndot.hr/ml over a 24-hour period during the chemotherapy phase.
18. The method of claim 15 wherein the patient is administered the BVDU, prodrug, or salt thereof during the recovery phase, and attains a BVDU blood level of about 0.02 to 50 µg/ml during the recovery phase.
19. The method of claim 18 wherein the patient is administered the BVDU, prodrug, or salt thereof during the chemotherapy phase, and attains a BVDU blood level of about 0.02 to 50 µg/ml during the chemotherapy phase.
20. The method of claim 15 wherein the patient is administered the BVDU, or prodrug, or salt thereof during the chemotherapy phase, and attains a BVDU AUC of at least about 0.5 µg.cndot.hr/ml over a 24-hour period during the recovery phase.
21. The method of claim 20 wherein the patient is administered the BVDU, prodrug, or salt thereof during the chemotherapy phase, and attains a BVDU AUC of at least about 0.5 µg.cndot.hr/ml over a 24-hour period during the chemotherapy phase.
22. The method of claim 15 wherein the BVDU, prodrug or salt thereof comprises the prodrug represented by the formula I:
or a salt thereof.
or a salt thereof.
23. A method for reducing chemoresistance compnsing administering to a patient in need thereof a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase.
24. A method for enhancing chemosensitivity comprising administering to a patient in need thereof a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase.
25. A method for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer, comprising administering a therapeutically effective amount of gemcitabme to a cancer patient in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in a recovery phase following the chemotherapy phase.
26. Use of a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in at least one of a chemotherapy phase and a recovery phase for treating a cancer treatable with gemcitabine in a patient in need thereof
27 The use of claim 26 wherein the cancer treatable with gemcitabine includes pancreatic cancer.
28. The use of claim 26 wherein the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, is used during the chemotherapy phase.
29. The use of claim 28 wherein the chemotherapy phase is about 1 to 5 days.
30. The use of claim 26 wherein the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, is used during the recovery phase.
31. The use of claim 30 wherein the recovery phase is about 1 to 10 days.
32. The use of claim 30 wherein the 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, is used during the chemotherapy phase.
33. The use of claim 32 wherein the chemotherapy phase is about 1 to 30 days.
34. The use of claim 33 wherein the recovery phase is about 1 to 30 days.
35. The use of claim 34 wherein no cytotoxic agent or 5-substituted nucleoside is used in a rest phase.
36. The use of claim 35 wherein the rest phase is about 8 to 60 days.
37. The use of claim 26 wherein the cytotoxic composition comprises a second cytotoxic agent other than gemcitabine.
38. The use of claim 37 wherein the second cytotoxic agent comprises a platinum compound.
39. The use of claim 38 wherein the second cytotoxic agent comprises cisplatin.
40. The use of claim 26 wherein the 5-substituted nucleoside, prodrug, or salt thereof, or combination of two or more thereof, comprises BVDU, or a prodrug, or salt thereof,.
41. The use of claim 40 wherein the BVDU, prodrug, or salt thereof is used during the chemotherapy phase, and the patient attains a BVDU blood level of about 0.02 to 50 µg/ml during the chemotherapy phase.
42. The use of claim 40 wherein the BVDU, prodrug, or salt thereof, is used during the chemotherapy phase, and the patient attains a BVDU AUC of at least about 0.5 µg.cndot.hr/ml over a 24-hour period during the chemotherapy phase.
43. The use of claim 40 wherein the BVDU, prodrug, or salt thereof is used during the recovery phase, and the patient attains a BVDU blood level of about 0.02 to 50 µg/ml during the recovery phase.
44. The use of claim 43 wherein the BVDU, prodrug, or salt thereof is used during the chemotherapy phase, and the patient attains a BVDU blood level of about 0.02 to 50 µg/ml during the chemotherapy phase.
45. The use of claim 40 wherein the BVDU, or prodrug, or salt thereof is used during the chemotherapy phase, and the patient attains a BVDU AUC of at least about 0.5 gg.cndot.hr/ml over a 24-hour period during the recovery phase.
46. The use of claim 45 wherein the BVDU, prodrug, or salt thereof is used during the chemotherapy phase, and the patient attains a BVDU AUC of at least about 0.5 µg.cndot.hr/ml over a 24-hour period during the chemotherapy phase.
47. The use of claim 40 wherein the BVDU, prodrug or salt thereof comprises the prodrug represented by the formula I:
or a salt thereof.
or a salt thereof.
48. Use of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase for reducing chemoresistance in a patient in need thereof.
49. Use of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in at least one of the chemotherapy phase or a recovery phase for enhancing chemosensitivity in a patient in need thereof.
50. Use of a therapeutically effective amount of gemcitabine in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in a recovery phase following the chemotherapy phase for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in a cancer patient.
51. Use of a therapeutically effective amount of a cytotoxic composition comprising gemcitabine in the preparation of a medicament for treating a cancer treatable with gemcitabine in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for treating the cancer in at least one of a chemotherapy phase and a recovery phase.
52. Use of a therapeutically effective amount of gemcitabine in the preparation of a medicament for reducing chemoresistance in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for reducing chemoresistance in the patient in at least one of the chemotherapy phase or a recovery phase.
53. Use of a therapeutically effective amount of gemcitabine in the preparation of a medicament for enhancing chemosensitivity in a patient in need thereof in a chemotherapy phase, and a therapeutically effective amount of a 5-substituted nucleoside, a prodrug or salt thereof, or combination of two or more thereof, in the preparation of the medicament for enhancing chemosensitivity in the patient in at least one of the chemotherapy phase or a recovery phase.
54. Use of a therapeutically effective amount of gemcitabine in the preparation of a medicament for enhancing the cytotoxic effect of gemcitabine in treatment of pancreatic cancer in a cancer patient in a chemotherapy phase, and a therapeutically effective amount of BVDU, or a prodrug, or salt thereof, in the preparation of the medicament for enhancing the cytotoxic effect of gemeitabine in treatment of pancreatic cancer in the cancer patient in a recovery phase following the chemotherapy phase.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002601558A CA2601558A1 (en) | 2007-09-11 | 2007-09-11 | Method of treating cancer by administration of 5-substituted nucleosides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002601558A CA2601558A1 (en) | 2007-09-11 | 2007-09-11 | Method of treating cancer by administration of 5-substituted nucleosides |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2601558A1 true CA2601558A1 (en) | 2009-03-11 |
Family
ID=40450938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002601558A Abandoned CA2601558A1 (en) | 2007-09-11 | 2007-09-11 | Method of treating cancer by administration of 5-substituted nucleosides |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2601558A1 (en) |
-
2007
- 2007-09-11 CA CA002601558A patent/CA2601558A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abotaleb et al. | Chemotherapeutic agents for the treatment of metastatic breast cancer: An update | |
Barnieh et al. | Progress towards a clinically-successful ATR inhibitor for cancer therapy | |
CN111886006B (en) | Combination therapy for the treatment of mastocytosis | |
Liu et al. | PARP inhibitors in ovarian cancer: current status and future promise | |
EP3169312B1 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
CA2789365A1 (en) | Methods for treating non-small cell lung cancer using 5-azacytidine | |
JP2017516802A (en) | Use of eribulin in the treatment of cancer | |
KR20180064540A (en) | MDM2 Inhibitor Therapy for Cancer Treatment | |
Ahmad et al. | Review of the use of topotecan in ovarian carcinoma | |
US20090068286A1 (en) | Method of treating cancer by administration of 5-substituted nucleosides | |
KR20190099253A (en) | Combination of Protein Kinase Inhibitors and Additional Chemotherapy Agents | |
TW201521742A (en) | CUSTIRSEN treatment with reduced toxicity | |
TR201702500A2 (en) | THE USE OF SERANIB-2 IN THE TREATMENT OF LUNG CANCER AND BREAST CANCER | |
JP6556701B2 (en) | Administration of NEDD8 activating enzyme inhibitor and chemotherapeutic agent | |
US10765675B2 (en) | Compositions and methods for treating Ewing family tumors | |
Geng et al. | Extensive therapeutic effects, underlying molecular mechanisms and disease treatment prediction of Metformin: a systematic review | |
Autorino et al. | Role of chemotherapy in hormone-refractory prostate cancer: Old issues, recent advances and new perspectives | |
CA2601558A1 (en) | Method of treating cancer by administration of 5-substituted nucleosides | |
CN117881396A (en) | Treatment of cancer with spirolactone and acyl fulvene combinations | |
EP2268287B1 (en) | Dosage regimens of an antitumor agent comprising deoxycytidine derivative | |
US20170136053A1 (en) | Novel pharmaceutical composition and uses thereof | |
EP2107906A2 (en) | Novel therapeutic use for treating leukaemia | |
Avan et al. | Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib | |
WO2019155448A1 (en) | Methods and combination therapy to treat biliary tract cancer | |
CA2519801C (en) | Use of 5-substituted nucleosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |